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Within the last decade, we have progressed from the belief that the healthy human lung is 
a sterile environment to attempts to study inter-kingdom interactions between microbial residents 
of the lungs. It has been repeatedly confirmed that the lungs contain both bacteria, predominantly 
from the Streptococcus, Veillonella, and Prevotella genera, and fungi, predominantly from the 
Cladosporium, Eurotium, Penicillium, and Aspergillus genera. The community composition as a 
whole undergoes shifts in every lung disease and condition that has been studied, including 
asthma, chronic obstructive pulmonary disorder, and cystic fibrosis. The studies that have 
observed these shifts have largely been descriptive, comparing the taxonomies present in healthy 
lungs to taxonomies in diseased lungs. Here we investigated the lung microbiome and 
relationships within the microbial community and between microbes and the host in a more 
quantitative and inferential manner. First, we introduced the lasso-penalized generalized linear 
mixed model (LassoGLMM) for microbiomes. LassoGLMM was applied to a short time-course 
study of the human oral bacterial microbiome with standard blood chemical measurements and 
to repeated measurements of the human lung bacterial microbiome and fungal mycobiome with 
local and systemic markers of inflammation. We sought to show that increased inflammation and 
other continuous clinical variables in human hosts are associated with distinct microbes present 
in the lung or oral microbiomes. Then, we examined cross-domain interactions between bacteria 
and fungi. Ecological interaction networks were inferred for the human lung and skin micro- and 
myco-biomes.  Networks limited to a single domain of life were compared with those that 
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include both bacteria and fungi to identify important components of the microbial community 
that would be overlooked in a single domain study. Finally, we explored the metabolism of the 
bacteria within the human lung using three different “-omics” datasets: taxonomic assignments 
from 16S rRNA gene sequences, gene families from metatranscriptomic sequences, and mass-to-
charge ratio (m/z) features from metabolomics. Correlations were examined between pairs of 
datasets and all three datasets were integrated to identify bacteria contributing metabolic 
processes that may have otherwise gone unnoticed, resulting in the first complete 
characterization of the metabolism of the human lung bacterial microbiome.     
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1.0  INTRODUCTION 
 
As far back as the 1880’s, healthy human intestines were known to be home to a multitude of 
bacteria (1); however, it is only in the past few years that scientists have recognized that the 
healthy lung also harbors bacteria (2, 3). Part of this discrepancy may be due to the fact that, 
until recently, only culturable bacteria could be studied. The rapid rise of next-generation 
sequencing (NGS) has enabled the recognition of unculturable bacteria, fungi, and other 
microbes in the lung and in other habitats.  
Although the existence of a distinct lung microbiome has been confirmed (4), it is still 
analyzed primarily using descriptive statistics (5, 6). This work focuses on investigating the lung 
microbiome and its relationship with the host in a quantitative and inferential manner. Other 
host-associated microbiomes, including in the human oral cavity, on the human skin, and in the 
macaque lung, were included to further validate the methods developed and used throughout. 
The results significantly enhance both our knowledge of the lung microbiome and the 
methodology available to analyze other host-associated microbiomes. 
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1.1 BACTERIA IN THE LUNGS 
Studies of the human-associated microbiome came on the heels of the human genome project 
and all its technological advancements. It allowed the characterization of this ‘second genome’ 
suspected of contributing to health and normal physiology. More recently, explorations of the 
respiratory tract have demonstrated the presence of bacteria and other micro-organisms in 
healthy lungs, including members of the Firmicutes, Bacteroidetes, and Proteobacteria phyla (2, 
3, 7). Each of these phyla is commonly found in other human-associated bacterial microbiomes 
(8, 9). Prominent genera from these phyla include Streptococcus and Veillonella from the 
Firmicutes phylum, and Prevotella from the Bacteroidetes phylum (Figure 1.1) (2, 4, 10–12). 
None of these genera are unique to the lung microbiome; what is likely to be specific to the lung 
environment are particular species or strains of microbes. Alternatively, some of these genera 
and species may have translocated to the lungs from the gut or other microbiome, a process that 
is known to occur under compromised immune conditions such as HIV-infection (13, 14). 
However, most studies rely on target gene sequencing of the 16S rRNA, which is an approach 
not considered to be reliable for taxonomic assignments below the genus level.  
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Figure 1.1 Relative abundance of bacterial genera and phyla in the lung brushings of healthy and asthmatic 
individuals. The inner ring displays the genera of bacteria while the outer ring displays the phyla. Any genera 
or phyla that represent over 10% of the reads are labeled with the percentage of reads. Figure adapted from 
(2). 
 
 
 
Because the genera prevalent in the lung microbiota are also highly abundant in the 
human oral microbiota, care has been taken to repeatedly prove that the bacteria within the lungs 
form their own community. Proof has come from both models and observations. From the 
modeling side, investigators have applied an ecological community assembly model for the 
neutral model of biodiversity. This model assumes that all inhabitable locations are the same and 
that all species have an equal chance of survival upon arrival in a given location (15). The 
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abundance of each species in a given community is dependent only on the total size of the local 
community and the immigration rate from the source community. The expected abundance, N, of 
the ith species is , where NT is the local community size and Pi is the relative 
abundance of species i in the source community (16). When this model was applied to the lung 
microbiome, using the oral microbiome as the source community, individual bacterial species 
were more abundant than would be expected based solely on immigration from the mouth (4, 
17). Both the details of how the neutral model was applied and the population studied impacted 
the results. A recent study found that the genera Ralstonia and Bosea were more prevalent in the 
lungs than expected from the oral wash source community of healthy non-smokers (4). In 
another study, the genera Catonella and Selenomonas were found to be more prevalent than 
expected from an oral wash source community in healthy patients (17). Both studies concluded 
that there are bacterial genera present in the lung microbiome that are not simply neutral 
immigrants from the mouth. Other studies have used ordination methods—an approach that plots 
the multi-dimensional community in a 2- or 3-dimensional space—to observe distinct 
community compositions of the mouth and lung microbiotas, displaying a separation between the 
oral and lung communities in the ordination plots (18, 19).  These ordination plots have been 
used to show that the bacterial community found in the lung samples could not have originated 
solely as carry-over or contamination from the oral cavity.   
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1.1.1 Bacteria During Disease 
  
Several human diseases have been associated with shifts in the composition of the bacteria in the 
lungs. Most of the conditions studied have been respiratory diseases, including cystic fibrosis 
(CF) (20, 21), asthma (2, 7), and chronic obstructive pulmonary disease (COPD) (3, 22–24), or 
led to lung transplantation (11, 25). These conditions have mostly unknown or unclear etiology, 
but it was hypothesized that the microbiome may play an important role. While some diseases 
studied have a clearer link to the bacteria present in the lungs, including active Mycobacterium 
tuberculosis (the causative agent of tuberculosis) infection (26), others, including HIV, have an 
indirect link to the lung microbiota (14, 27). In the case of HIV, an association is suspected 
between the microbiota and subtle lung immune deficits seen even in well-controlled HIV 
infection.  
Each disease studied has its own unique shifts in the composition of bacteria present. 
Cystic fibrosis patients have decreased community diversity in their sputum (28, 29) while 
asthmatic patients have increased community diversity in their lower respiratory tract (7, 30). 
Specifically, asthma has been associated with increased abundance of members of the 
Proteobacteria phylum (2, 7, 30). COPD may be unique among the respiratory diseases as shifts 
in the microbiota are only seen when the disease is severe (3, 22, 31, 32). In severe COPD there 
is decreased abundance of members of the Bacteroidetes phylum, and accompanying increases in 
potentially pathogenic members of the Proteobacteria, including members of the Pseudomonas 
and Haemophilus genera (3, 33, 34). Similarly, bronchoalveolar lavages (BALs) from lung 
transplant patients have been shown to be enriched with Pseudomonas and other members of the 
Proteobacteria phylum (11, 25, 35, 36). However, each disease appears to be associated with 
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lung bacterial communities that are different, driven by the variety of genera in the 
Proteobacteria phylum and diversity of species and strains within the Pseudomonas genera 
(Figure 1.2) (12). 
One commonality across all diseases studied is that the direction of causality remains 
unknown. Because most studies are cross-sectional, or represent a single point in time, 
investigators are unable to determine if the shifts in the disease are the result or the cause of a 
shifting microbiota. This directionality will become more clear as microbiome studies 
incorporate other technologies to study the metabolism and mechanisms of the community, and 
through prospective, longitudinal studies that follow patients from early disease onset through 
clinical exacerbations.  
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Figure 1.2 Ordination plot of bacterial communities from the lungs of patients with different respiratory 
diseases as labeled. When plotted together, each disease separates from healthy lungs in its own way. COPD = 
chronic obstructive pulmonary disease; IPF = idiopathic pulmonary fibrosis. Figure from (12), Copyright 
2016, Annual Reviews. 
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1.2 FUNGI IN THE LUNGS1  
 
In less than a decade, we have progressed from believing that healthy lungs are a sterile 
environment to studying inter-kingdom interactions between microbial residents of the lung. In 
part due to the debate about the sterility of the lungs, next generation sequencing (NGS)-based 
studies of the lung microbiome have lagged behind those of the gut microbiome, with the first 
studies of the lung microbiome being published in 2010 and 2011 (2, 3, 7). These early NGS 
studies, and many studies since, focused exclusively on the bacteria present in the lungs under 
health and disease. However, the microbial community that inhabits the lungs also contains 
viruses, fungi, and other eukaryotes.  
1.2.1 Why is the lung mycobiome important? 
In addition to causing clinical infections, the lung mycobiome may have profound inflammatory 
effects that can cause or worsen lung disease. Similar to bacterial pathogens, fungi contain 
pathogen-associated molecular patterns (PAMPS) such as glucans, chitin, and mannans present 
in the fungal cell wall (37, 38). These PAMPs are recognized by pathogen recognition receptors 
(PRRs) that then activate immune cells leading to inflammation (Figure 1.3). Activation of 
macrophages, T cells, and B cells leads to cytokine release and immune activation. Both the 
adaptive and innate immune responses are triggered by fungi, and the respiratory epithelium 
plays a key role in the response to fungi. Fungi have been linked to such chronic lung diseases as 
                                                 
1 This work was published in Virulence as “The lung mycobiome in the next-generation sequencing era” 
(169)  
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asthma and COPD (39, 40). Given the ubiquity of fungi in the environment, the potential 
respiratory exposure to fungi, and the ability of fungi to trigger inflammation, the mycobiome 
may play a key role in shaping the respiratory immune response and contribute to lung damage.     
 
 
 
 
Figure 1.3 Interaction between the mycobiome and the immune system. When pattern recognition receptors 
(PRRs) recognize the pathogen-associated molecular patterns (PAMPs) on fungal cell walls, macrophages, T 
cells, and B cells are activated. The fate of the actived T cells is determined by the cytokines that are 
stimulated. INF, interferon; IL, interleukin; TNF, tumor necrosis factor. Figure from ref. (41) 
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1.2.2 What do we know about the lung mycobiome? 
To date, there have been fewer than 10 NGS lung mycobiome papers published. Despite this low 
number, several themes emerge from the literature: (1) fungi are present in the human respiratory 
tract, even during health; (2) the fungi present in the respiratory tract are highly variable between 
individuals; and (3) many diseases are accompanied by decreased diversity of fungi in the lungs.   
Fungi found in the human respiratory tract cover a range of phylogenies, but are 
predominantly from the Dikarya sub-kingdom, which is composed of the phyla Ascomycota and 
Basidiomycota. In fact, the most common taxa identified in healthy lung samples were the family 
Davidiellaceae, and the genera Cladosporium, Eurotium, Penicillium, and Aspergillus (25). 
Other genera found in healthy individuals include Candida, Neosartorya, Malassezia, 
Hyphodontia, Kluyveromyces, and Pneumocystis (20) (Figure 1.4). These eleven taxa cover the 
range of fungal growth patterns from filamentous, to yeast and yeast-like. Many of these genera,  
including Cladosporium, Aspergillus, Candida, Malassezia, and Pneumocystis, contain species 
that are either pathogenic to humans or cause allergic reactions (42–46). On the other end of the 
spectrum, the genera Penicillium includes producers of the antibiotic penicillin (47).   
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Figure 1.4 Distribution of fungal phyla in the sputum of healthy individuals(38). The inner ring displays the 
class of fungi while the outer ring displays the phyla. Any class or phyla that represented over 10% of the 
reads is labeled with its percentage of reads is labeled with its percentage of reads and classes or phyla below 
0.1% are not represented. 
 
 
 
The fungi present in the respiratory tract are also highly variable between individuals. 
Even in patients with the same disease, different patients have been shown to harbor distinct 
fungal communities (48). In our experience, the number of “private species”, those present in 
only one individual, can be greater than the number of species shared across samples. Whether 
this difference is due to mis-identification of the fungi (perhaps due to a sequencing error) or a 
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patient’s unique environmental exposures has yet to be determined. It has been proposed that the 
macromycetes (or macroscopic fungi commonly known as mushrooms) observed in a subset of 
samples represent the outdoor environment that a patient is exposed to as they often contain 
wood-inhabiting fungi and cereal grain pathogens (20). Even the level of fungal diversity in the 
lungs is highly variable between individuals. Compared to bacterial diversity in the lungs, 
average fungal diversity in the same samples is consistently lower (49) but has a higher 
coefficient of variation, or ratio of standard deviation to the mean. As an example, in a subset of 
35 BAL samples from our study of the lung mycobiome in HIV-infected and uninfected 
individuals for which we have both 16S rRNA and ITS sequence data (40), the coefficient of 
variation is 22.9% for bacterial diversity, as measured by the Shannon diversity index, and is 
73.9% for fungal diversity. Other factors, including patient health and environmental exposures, 
appear to have a greater impact on the diversity of the fungi than of the bacteria, the latter being 
considered relatively stable.   
Only a limited number of diseases have been examined for their impact on, or association 
with, the lung mycobiome. Most diseases that have been studied, including CF, asthma, and 
COPD, as well as lung transplant, have been associated with decreases in fungal diversity (20, 
25, 40, 50). Across these conditions, lower fungal diversity is correlated with lower respiratory 
function. The reduced diversity may be caused by an overgrowth of a single fungal species, or by 
the loss of rare species that comes with a reduction in overall fungal abundance. 
CF has received the most attention with studies that range from correlating community 
characteristics with patient health indicators to comparing NGS and sequencing detection to 
community stability over time. Delhaes et al examined sputum of four CF patients, each sampled 
twice, and found that both bacterial and fungal community richness was positively correlated 
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with indicators of health and lung function (20), i.e. more fungal species were seen in the 
patients with the lowest disease severity scores, highest body-mass indices, highest forced vital 
capacity, and highest forced expiratory volume in 1 second. Harrison et al found that over 82% 
of the species identified by sequencing were not found by culture-based methods, which detected 
fungi in only 27% of the sputum samples from 55 CF patients compared to a 90% detection rate 
by sequencing (50). Willger and colleagues sought to compare sputum from six CF patients 
before and after antimicrobial therapy and found that the fungal communities were relatively 
stable (51). Similarly, a study of 89 sputum samples from 28 CF patients showed that the fungal 
communities were stable through clinical exacerbation and treatment (48). This study combined 
NGS of the mycobiome with phenotypic and genotypic analysis of Candida isolates from the 
samples to identify mutations leading to the filamentous phenotype in the presence of 
filamentation repressive cues from the bacteria Pseudomonas aeruginosa (48). It is the 
filamentous phenotype that is considered pathogenic and evading the repressive signals from 
other members of the microbiome could lead to Candida infection. 
Lung transplantation could impact the mycobiome due to the immunosuppression and 
antibiotics received by recipients as well as structural changes in the lung.  In general, lung 
transplant recipients have reduced fungal richness and increased fungal abundance compared to 
healthy controls. For example, Charlson et al found that combined bacterial and fungal 
community richness was reduced in BALs from 21 lung transplant patients compared to healthy 
controls and richness was lowest in patients who had a transplant due to CF (25). All transplant 
patients were receiving antibiotics in addition to immunosuppression at the time of sampling, 
making it difficult to attribute causality in these changes. In the four patients with high fungal 
amplification from BAL, the dominant species (Candida albicans in three samples and 
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Aspergillus fumigatus in one sample) was also found by culture methods, which were only able 
to identify four species: C. albicans, A. fumigatus, Aspergillus flavus, and Paecilomyces lilacinus 
(also known as Paecilomyces lilacinus). Expanding this dataset to include a total of 149 BAL 
samples from healthy subjects, HIV-infected subjects, subjects with mixed lung disease, and 
lung transplant recipients, Bittinger et al showed that fungal abundance increases from healthy 
subjects to lung transplant recipients with HIV-infected subjects and subjects with mixed lung 
disease falling in the middle (49). To ensure that they were counting species truly present in the 
lungs, they used DNA quantification to filter out any species that were likely to have come from 
contamination before calculating species abundances. 
Asthma, COPD, and pneumonia have been less well-studied, with only a single paper 
each examining shifts in lung mycobiome communities. For asthma, a case-control study to 
compare induced sputum samples of 30 subjects with asthma to that of 13 control subjects found 
90 species to be more abundant in asthma and 46 species to be more abundant in the controls 
(39). Species with more than a 5% increase in abundance between the asthma and control sample 
pools were Psathyrella candolleana, Malassezia pachydermatis, and Termitomyces clypeatus, 
none of which were seen in the control sample pool. Species with more than a 5% decrease in 
abundance between the asthma and control sample pools were Eremothecium sinecaudum, 
Systenostrema alba, Cladosporium clasdosporioides, and Vanderwaltozyma polyspora. We 
published the only paper on COPD where we first compared HIV-infected to HIV-uninfected 
individuals and then compared HIV-infected individuals with COPD to HIV-infected with 
normal lung function (40). We used an overlap of multiple methods to identify overrepresented 
species in the BAL of 32 HIV-infected individuals, 10 with and 22 without COPD, and 24 HIV-
uninfected controls (40). We found Pneumocystis jirovecii to be the most distinguishing species 
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as it was overrepresented in both HIV and COPD. Finally, in the only published study on 
pneumonia, which is the largest lung mycobiome study to date, Krause et al compared BALs 
from 87 healthy controls, 18 patients with extrapulmonary infection on antibiotics, 8 intensive 
care unit patients without antibiotics, 23 intensive care unit patients with extrapulmonary 
infection on antibiotics, 34 intensive care unit patients with pneumonia on antibiotics, and 32 
patients with candidemia (52). They focused on Candida and found that intensive care unit 
admission, but not antibiotic therapy, shifted the lung mycobiome to be dominated by Candida. 
Even this recent study still used culture-based fungal identification as the gold standard for 
fungal identification, as this is standard practice in a clinical setting. 
 
1.3 OTHER MICROBES IN THE LUNGS 
 
While a wide variety of viruses have been identified in healthy lungs, most are bacteriophages, 
viruses that infect bacteria. Across individuals, there appears to be a core functionality of this 
virome of the lung (53). However, if the lung micro- and myco-biomes are considered new 
fields, the lung virome is truly nascent. While the virome encompasses both DNA and RNA 
viruses, the studies that have been published to date examine only the DNA viruses and focus on 
the viruses that infect the human hosts (53, 54).  
In addition to viruses, other non-bacterial, non-fungal microbes in the lungs consist of 
other eukaryotes. These include protists and helminths, both of which have been known to infect 
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the human lung (55). However, neither of these groups has been studied in the healthy human 
lung. Therefore, neither these eukaryotes nor viruses will be included in this work. 
 
1.4 CHALLENGES TO STUDYING THE LUNG MICROBIOME2 
 
Studies of the lung microbiome and mycobiome may be limited because of the numerous 
challenges that exist at every step. The challenges begin with sampling the lung and continue 
through sample processing. These are followed by tough choices with regards to amplification 
and sequencing and more challenges to process the sequencing data. Finally, the historical 
system of naming fungi that resulted in multiple names for a single species has created 
difficulties now that NGS is used to define and identify species. Because many of these 
challenges are applicable to all NGS microbiome and mycobiome studies, we have included only 
a brief overview of each one and its relevance to the lung communities.  
The human lungs are difficult to access. The two most common means of sampling the 
lungs are induced sputum (IS) and BAL. Both methods run the risk of contamination from the 
upper respiratory tract. IS is obtained by having subjects cough after inhalation of hypertonic 
solution, potentially introducing mouth microbes during collection, and the bronchoscope may 
introduce upper respiratory microbes to the lungs during passage through the nose or mouth. 
However, it has been shown that both IS and BAL mycobiomes are distinct from the oral 
                                                 
2 This work was published in Virulence as “The lung mycobiome in the next-generation sequencing era” 
(169) 
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mycobiome (40). We have shown that there are differences in the fungal communities of IS and 
BAL, likely because the two methods sample the lungs differently: IS samples from a greater 
anatomic region of the lung, while BAL samples from a subset of the alveoli. Different 
environmental conditions existing in different portions of the lungs, or microenvironments, will 
be indistinguishable in an IS sample, but may be missed entirely by a BAL. The choice of 
sampling method should be selected based on the question under investigation, or, in the case of 
pre-existing samples, the limits of the sampling method should be addressed to the extent 
possible.  
Once a sample is obtained, DNA needs to be extracted. As with any NGS-based study of 
microbes, one of the first steps is to break open the cell. While this is relatively simple for 
bacteria, the fungal cell wall is composed of a combination of glucans and chitin, for which 
proportions vary by fungal growth patterns (56). The varying composition of the fungal cell wall 
leads to a range of tensile strengths, and there are a number of methods to break open the cell 
wall that vary in harshness. For the purposes of extracting DNA from both yeasts and 
filamentous fungi, mechanical disintegration has proven most effective (57); however, this 
method runs the risk of shearing the DNA and therefore must be carefully calibrated for the 
given sample composition.  
The harsh mechanical treatment to break open the fungal cell walls also creates a 
challenge by releasing DNA from other cells present in the lung sample, both bacterial and 
human. The extra DNA released from non-target cells, along with any DNA found in the 
laboratory reagents (a recent study attempted to characterize the bacteria found in DNA 
extraction kits (58), but no equivalent study has been performed for fungi), necessitates careful 
primer design for amplification. Common targets for amplification include the gene encoding 
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one or more of the hypervariable regions of the 16S ribosomal RNA (rRNA) for bacteria (59), 
and the 18S rRNA or the internal transcribed spacer (ITS) region(s) located between the 18S and 
26S rRNA genes (60) for fungi. Each of the fungal targets has its own benefits and drawbacks. 
Specifically, the 18S rRNA gene is conserved across all eukaryotes, so targeting this gene for 
amplification and sequencing of fungi will include non-fungal microbial eukaryotes. Because the 
18S rRNA gene is conserved across all eukaryotes, amplifying this region of the genome can 
also amplify any human DNA present in the sample, depending on the specificity of the primers. 
Due to the low biomass of microbes in the lung, the amount of human DNA in the sample prior 
to targeted amplification is bound to be higher than the amount of fungal DNA. In contrast, the 
ITS region is more diverse across eukaryotes and primers have been designed specifically for the 
amplification of fungal DNA (61), to the exclusion of all other eukaryotes. Some of these 
primers are narrowly targeted such that they introduce bias towards particular fungal phyla, 
another issue worthy of careful consideration. The diversity of the ITS region and the specificity 
of the primers combine to allow a greater depth of taxonomic assignment, often down to the 
species level. It is this advantage that has led the ITS region to be the “official primary barcoding 
marker” for fungi (61). However, because it is a non-coding region, ITS sequences cannot be 
used to determine phylogenetic relationships between unidentified fungi. 
One of the greatest challenges following sequencing is a lack of data, specifically a lack 
of reference genomes. For bacteria, the GreenGenes 16S rRNA gene database is a common 
reference database (62, 63), but it is missing references that may be clinically relevant to 
respiratory disease such as the Trophyrema genus, which has been shown to be enriched in the 
lungs of HIV-infected patients (14). For fungi, the UNITE database of fungal ITS sequences 
represents the largest collection of fungal sequences and (as of version 7) contains more than 
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64,500 “species hypotheses” at the 1% similarity threshold, where a species hypothesis is any 
group of sequences that are no more distant than the similarity threshold (64). Compared to the 
over 203,000 bacterial species hypotheses at the 1% similarity threshold in the May, 2013 release 
of the GreenGenes 16S rRNA gene database (63), the number of fungal reference species seems 
small. The sequences within the UNITE database are heavily biased (87% of species hypotheses) 
towards the Dikarya sub-kingdom (64) (Figure 1.5). While this bias may accurately represent 
the distribution of fungal species, or may simply stem from UNITE’s history as a database for 
plant root fungi (65), it certainly explains why the majority of species identified in the lungs 
belong to this sub-kingdom.  
Even after the sequences are identified, there are still challenges to be overcome in 
mycobiome studies that are not as prevalent in microbiome studies. Despite years of expert 
mycologists pushing for each fungus to have a single species name, many fungi still have one 
name for their sexual reproductive stage (or teleomorph) and one name for their asexual 
reproductive stage (or anamorph) (66, 67). The problem with this dual naming system in the 
NGS era is two-fold. First, it can complicate a search for knowledge prior to the NGS era. Many 
older studies reference only one name and it can be unclear if the results apply to the opposite 
morph. There is no way to identify which morph is present in a sample based on its DNA. It can 
also be that the higher order taxonomic assignments, such as family and order, of the two morphs 
are different, leading to phylogenetic confusion about the placement of the species as a whole. 
Uncertain phylogenetic placement and phylogenetic restructuring result in taxonomic hierarchies 
that include incertae sedis (Latin for “of uncertain placement”), as seen in the taxonomies of 
members of the former phyla Zygomycota (68). The second problem with a dual naming system 
is that sample sequences may have two or more identical matches when a database has reference 
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sequences for both the teleomorph and anamorph causing ambiguous assignments. Curated 
databases such as Mycobank (69) can aid in the reduction of duplicate reference sequences, but 
similar curation is not readily available for pre-NGS knowledge.  
 
 
 
 
Figure 1.5 Distribution of fungal phyla in the UNITE database (64). The chart shows the breakdown of phyla 
of the 64,500 “species hypotheses” at the 1% similarity threshold found in the UNITE ITS database. Phyla 
that represent over 10% of the species hypotheses are labeled with its percentage of species hypotheses.   
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1.5 FUTURE OF LUNG MICROBIOME RESEARCH 
 
Many of the challenges to studying the lung microbiome and mycobiome are unavoidable. There 
is likely never going to be easy access to the human lung that avoids the upper respiratory tract, 
and the microbes in the lung will always be low in biomass. However, improvement is possible 
in primer design, reference databases, and analytic methods. Going forward, many of the 
advances made in the study of the lung bacteria will aid in the study of the lung mycobiome. 
Once the sequencing data are collapsed into a “biom” file or taxa table (a table that displays the 
abundance of each taxonomic group for every sample) it makes little difference if the taxa are 
bacterial or fungal. All of the statistical methods to handle the abnormal distributions (70) and 
complex study designs associated with bacterial studies can be used on fungal studies with little 
or no modifications. Similarly, as bacterial studies shift from cross-sectional to longitudinal, so 
too should fungal studies. There have already been studies into the daily changes in bacterial 
communities that occur during CF and its exacerbations (21) but fungi were not examined. The 
tools, including sequencing capacity, that are developed to handle daily sampling of the bacteria 
can also be put to use to analyze the fungi present during the same time period. 
When more studies include both bacterial and fungal amplicon sequences from target 
gene sequencing, we can begin to look at cross-kingdom interactions. Interactions between 
bacteria and fungi are important among oral microbiota (71) and identified as an emerging field 
across biology (72), so they will no doubt be important to the study of the lung microbiota. 
Looking farther into the future, as amplicon sequencing gives way to whole metagenome and 
whole metatranscriptome sequencing, these delineations between bacterial and fungal 
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communities will fall away. Both kingdoms will be sequenced simultaneously and their 
members’ abundance and transcriptional activity, relative to each other, will be apparent.  
Another avenue for future investigation will be the mechanisms of interactions between 
the microbiome, the mycobiome, and the host.  As a part of the mucosal immune system, the 
lungs and the microbes within, play an important role in human health and disease. The impact 
of inflammation on the development of many lung diseases represents an area of active 
investigation, one in which the contribution from the lung microbiome or mycobiome could 
prove crucial to understanding. 
In both the short- and long-term, the critical need for the lung microbiome and 
mycobiome is more data, in the forms of reference sequences and additional studies. Adding 
sequences to reference databases by sequencing more bacteria and fungi will help in identifying 
species that are currently unclassifiable. These sequences can come from culturing some of the 
estimated 99% of the world’s bacteria (73, 74) and fungi (75) that have yet to be reliably grown 
in the lab, or from assembling genomes present in deeply sequenced metagenomes. The latter 
makes it possible to obtain sequences from unculturable microbes without the time and 
manpower required to optimize the culturing conditions of newly cultured organisms. The other, 
and perhaps more important, way to contribute to the knowledge of the lung microbiome and 
mycobiome is to perform more studies. Additional lung microbiome and mycobiome studies will 
provide more information about the changes in the bacteria and fungi present under health and 
disease conditions and will help to explain the role of microbes in influencing the respiratory 
immune response.  
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1.6 OVERVIEW 
 
The introduction highlighted the importance of including longitudinal data, taking into account 
cross-kingdom interactions, and developing new analytical methods in our exploration of the 
lung microbiome. This thesis is presented as three separate sections that touch on each of those 
aspects. In the first part, the lasso-penalized generalized linear mixed model (LassoGLMM) for 
microbiomes is introduced. LassoGLMM is applied to a short time-course study of the human 
oral bacterial microbiome with standard blood chemical measurements. LassoGLMM is then 
applied to repeated measurements of the human lung bacterial microbiome and fungal 
mycobiome with local and systemic markers of inflammation.  
In the second part, cross-domain interactions between bacteria and fungi are examined. 
Ecological interaction networks are inferred for the macaque lung, human lung, and human skin 
micro- and mycobiomes. In the human lung and human skin studies, networks limited to a single 
domain of life are compared with those that include both bacteria and fungi.  
Finally, in the third section, the metabolism of the bacteria within the human lung is 
explored using three different “-omics” datasets. Each dataset—taxonomic assignments from 
16S rRNA gene sequences, gene families from metatranscriptomic sequences, and mass-to-
charge ratio (m/z) features from metabolomics—is explored for its associations with COPD and 
HIV. Then, correlations are examined between pairs of datasets and finally, all three datasets are 
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integrated to identify bacteria contributing the metabolic processes that may have otherwise gone 
unnoticed. 
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2.0  MEASURING ASSOCIATIONS BETWEEN THE MICROBIOTA AND 
REPEATED MEASURES OF CONTINUOUS CLINICAL VARIABLES USING A 
LASSO-PENALIZED GENERALIZED LINEAR MIXED MODEL3 
 
2.1 BACKGROUND 
Epidemiologic studies, ranging from clinical trials to observational studies, often include the 
collection of demographics, disease symptoms, treatment, diagnostic tests, and clinical 
laboratory information. Recent evidence that the human microbiome influences disease 
occurrence (31, 76) has led to interest in how the microbiome may more generally impact 
clinical and treatment outcomes, and the natural history of a disease. While continuous clinical 
measures are used to describe and to identify risk subgroups in the patient population, the 
relationship between these measures and the microbiome is rarely analyzed. This rarity is in part 
caused by methodologic limitations in applying current microbiome and analytic techniques to 
continuous clinical data. 
                                                 
3 Paper under review. 
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One stumbling block to analyzing the microbiome in the context of clinical variables 
comes from repeated measurements, i.e. the same measurement taken at multiple time points or 
multiple measurements made at a single time point. Even in non-equilibrated communities, 
where variance between repeated measures is high, measurements of the microbial community 
are expected to be highly correlated with each other, thus presenting a problem for standard 
statistical methods. However, repeated measures can provide important data for processes that 
evolve or change over time. Techniques to analyze repeated measures would be of use to the 
microbiome field as they are often necessary to obtain a more complete understanding of a 
system of interest. 
An additional challenge in analyzing clinical outcomes and biomarkers in light of the 
microbiome is that the outcomes are often continuous rather than dichotomous variables. 
Continuous variables are those that can take on any value within a given range, and when they 
are converted to a categorical or dichotomous format, in some instances, information is lost. In 
practice, count variables, although not technically continuous, are treated as continuous 
variables. These continuous variables, as opposed to categorical variables, have repeatedly been 
dichotomized in the microbiome literature (33, 49) with the potential for loss of nuance in the 
relationship between them and the microbiota.  
Mixed models—both generalized linear mixed models (GLMMs) and linear mixed 
models—have been used in ecology at least as long as methods for microbiome studies have 
existed (77). These models incorporate both fixed effects that are the same for every observation 
or sample, and random effects that apply to select samples or groups of samples. Through the use 
of random effects, linear mixed models are designed to handle repeated measures and other 
complex study designs (77). In addition, generalized linear models (GLMs) attempt to model 
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data that do not follow a traditional normal distribution. The linear relationship between the 
outcome and predictors is redefined as the set of linear predictors and their relationship to the 
expected value of the outcome via a “link” function. This link function, along with the variance 
of the expected value of the outcome, are selected from the members of the exponential 
distribution family, which are well known.  
We focused on the GLMM method because it is the only analysis method that handles 
both continuous variables and repeated measures. GLMMs have just recently been incorporated 
into microbiome studies (31, 78, 79). These early adopters of the GLMM methods primarily use 
the sample group (i.e. sample site, treatment, pregnant/non-pregnant) to explain species 
abundance. When combined with a penalty parameter—an additional term that eliminates 
extraneous explanatory variables—GLMMs can use species abundance to explain clinical 
laboratory measurements (including continuous measurements such as cholesterol, blood 
glucose, cytokines) and other clinical measures. 
Penalized regression models have been used in genomics and metagenomics studies for 
several years (80). Of the two most basic penalty types, lasso and ridge (also known as L1 and 
L2, respectively), the lasso penalty has the advantage of performing variable selection by 
reducing some coefficients to zero. In comparison, the ridge penalty shrinks some coefficients 
towards but not all the way to zero. The elastic net penalty, which is the combination of the lasso 
and ridge penalties, reduces some coefficients to zero and shrinks others, thereby limiting its 
capacity to perform variable selection (81). Only the lasso penalty performs variable selection 
without having to decide on a coefficient size threshold to define association.  
The lasso penalized generalized linear mixed model (LassoGLMM), originally developed 
in 2011 for sports statistics and human-computer interactions (82, 83), has many properties that 
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make it well-suited for microbiome applications. This model leverages the power gained by 
repeated measures and compensates for the large number of variables. The lasso penalty forces 
some coefficients to be equal to zero, leaving only those variables (or in our case, microbes) with 
the strongest associations with non-zero coefficients. This feature resolves the problem of having 
many more explanatory variables than observations. The mixed effects in the LassoGLMM also 
allow for repeated measures by including a random effect for each subject and repeated 
measurement.  
We now present an application of the LassoGLMM to examine the relationships between 
the microbiome and continuous variables related to health and inflammation from clinical studies 
of the respiratory tract. We applied a LassoGLMM with a correlation-based variable screening 
step to two microbiome datasets: a 16S rRNA gene survey of the oral microbiota from the Oral 
Cyclosporine in Chronic Obstructive Pulmonary Disease study (OC-COPD; clinicaltrials.gov ID: 
NCT00974142, a randomized controlled clinical trial), and a combination bacterial 16S rRNA 
gene and fungal Internal Transcribed Spacer (ITS) survey of the bronchoalveolar lavage (BAL) 
for the Pittsburgh site of Lung HIV Microbiome Project (LHMP; clinical trials ID: 
NCT00870857, an observational cohort study). In the OC-COPD study, we sought to discover 
associations between the oral microbiota and laboratory values measured in peripheral blood. In 
the LHMP, we aimed to identify which bacteria and fungi were associated with increased 
inflammation both locally in the lungs and systemically in the blood.  
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2.2 METHODS 
Multiple specimens including oral washes and BAL for microbiota characterization, and blood 
for chemistry, inflammatory markers, and other laboratory measurements were collected as part 
of the OC-COPD and the LHMP. The OC-COPD dataset included 15 samples from 8 individuals 
at pre-randomization (trial week 0) and at trial week 16 (one participant did not have a sample 
for the pre-randomization visit). These OC-COPD participants, who were sequentially enrolled 
from the parent trial, had advanced COPD but were free of active infections. Specific inclusion 
criteria included: between 45-80 years of age, having advanced COPD (defined as forced 
expiratory volume in 1 second, FEV1, between 25% and 60% predicted), and being non-
responsive to traditional inhaler therapy. Once enrolled, participants were randomized to receive 
the test drug, cyclosporine (an immune suppressant), or placebo for 16 weeks. Additional 
eligibility requirements for the trial are described at clinicaltrials.gov, identifier NCT00974142. 
Laboratory outcomes include 32 blood measurements found in a typical blood chemistry panel 
with electrolytes. Clinical independent variables used were gender and treatment group (test drug 
or placebo). 
The LHMP lung microbiome dataset contained 30 samples from 21 participants who had 
BAL performed on their right and left lungs at the same clinical visit. This group included both 
HIV-infected (HIV+; N=11) and HIV-uninfected (HIV-; N=10) individuals, and could be 
classified as current smokers (N=3), former smokers (defined as having quit more than 6 months 
prior to the study; N=3), and never smokers (defined as having smoked fewer than 100 cigarettes 
in a lifetime; N=15). Inclusion criteria included no use of antibiotics in the past three months and 
no evidence of acute respiratory disease for four weeks. The lung microbiome was sampled by 
BAL following an oral wash and gargle with antiseptic mouthwash. Specific inclusion criteria 
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and sampling procedures can be found in (4). The 16S and ITS rRNA sequence data are 
described in (4) and (40), respectively. Laboratory outcome variables include 12 cytokines 
measured in both the BAL and the blood; 6 cytokines that were detectible in less than 10% of the 
samples were excluded from further analysis. Clinical independent variables used were HIV 
status and smoking history category.  
 
2.2.1 Sequence Data Processing 
The sample processing procedures were performed as previously described in (4) and (40). In 
brief, all samples had DNA extracted using standard techniques with the PowerSoil® DNA 
Isolation Kit from MO BIO (Carlsbad, CA). For the OC-COPD, the bacterial V4 hyper-variable 
region of the 16S rRNA gene was amplified and sequenced on the Illumina MiSeq platform. For 
the LHMP, the hyper-variable regions 1 through 3 (V1-V3) were amplified and sequenced using 
the Roche 454 GS-FLX platform with Titanium chemistry. For fungal DNA sequencing, the 
ITS1 was amplified and sequenced on the Ion PGMTM Sequencer using the 400 bp protocol (60). 
Sequences were processed using the QIIME pipeline version 1.7 (84) with default settings for de 
novo Operational Taxonomic Unit (OTU) picking. Bacterial 16S rRNA gene sequences were 
clustered at 97% similarity and fungal ITS sequences were clustered at 99% similarity. 
Additional processing and taxonomic assignment for the ITS sequences was performed using 
FHiTINGS (85). Samples with fewer than 1,000 16S rRNA bacterial reads, and samples with 
fewer than 100 ITS fungal reads were considered to have failed and were removed from further 
analysis.  
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After initial taxonomic assignments were made using the default settings in QIIME or 
FHiTINGS, OTUs were combined by taxonomic assignment at the genus level. For each 
kingdom, all genera counts were normalized using total sum scaling, also known as relative 
abundance. Any bacterial genus present in fewer than half of the samples was removed. Due to 
greater diversity between samples in the fungal genera, we reduced this cut off to remove genera 
present in fewer than 10% of the samples. 
 
2.2.2 Variable Screening Step 
The number of genera present is often at least an order of magnitude larger than the number of 
subjects sampled. When seeking to assess the relationship of microbiota components with 
clinical variables, the mismatch in number of subjects versus microbial variables presents an 
analytic challenge. We overcome this problem by preceding LassoGLMM regression with a 
variable screening step based on correlation. For each response-genera pair, Spearman 
correlations deemed significant (p ≤ 0.05) without multiple testing correction were used as 
independent variables in the regression model. Figure 2.1 shows an overview of this two-step 
method. 
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Figure 2.1 Overview of the two-step LassoGLMM model developed. Species (or OTUs or any other 
explanatory variables of interest) are divided into those that are correlated with the dependent continuous 
variable, Y, and those that are not. Species that are correlated are stored in a matrix X. Relevant categorical 
variables, found through a review of expert literature or other means, are stored in a matrix W. Indicators of 
repeated measures such as patient ID are stored in matrix Z. Matrices X, W, and Z are entered into a 
generalized linear mixed model to be regressed on outcome variable Y. Coefficient β for matrix X and 
coefficient B for W are subjected to the lasso penalty. Any species that retain non-zero coefficients are 
considered strongly associated with the dependent variable Y. 
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2.2.3 Lasso-Penalized Generalized Linear Mixed Model 
The LassoGLMM combines variable selection with the flexibility to account for repeated 
measures and other random effects. It can be built up from the random-intercept linear mixed 
model: 
, (3.1) 
where Y is the response variable, or outcome of interest, X is the matrix of the fixed effects 
including genera abundances, β is the vector of coefficients associated with the fixed effects, Z is 
the matrix form of the random effects including patient, b is the vector of coefficients associated 
with the random effects, and ε is the random error. For example, we modeled the response 
variable, Y, of blood glucose on the relative abundance of bacterial genera in the mouth, 
formatted as a matrix X, while accounting for the individual participant as a random effect, Z. 
This traditional format highlights the breakdown of independent variables into two groups: the 
fixed effects and the random effects. Fixed effects are those that are the same for all observations 
or samples, for example genera abundances and disease status. Random effects are those that are 
unique to each observation or group of observations, for example the study participant or time 
point. The unit of repeated measurement, in our case the individual, is always considered a 
random effect. In the OC-COPD study, the same subject was sampled at a pre-randomization 
visit and 16 weeks later. Although we did not expect there to be high correlation between 
individuals, we included the visit as a random effect to account for any seasonal or batch 
processing effects. In the LHMP study, the right lung and the left lung were sampled in the same 
subject in the same visit in a randomized order (right first, or left first). We included an identifier 
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for the first and second sides to be sampled as a random effect to account for any order bias, 
including the possibility of higher contamination from the upper respiratory tract in the first side. 
The fixed effects can be split again into continuous and categorical variables, and the 
resulting formula becomes: 
, (3.2) 
where X now only contains the continuous fixed effects and W is the matrix form of the 'dummy' 
variables indicating each level among the categorical variables including disease status. This 
split is important for the penalization of the categorical variables described below. In our 
regression models we included the following categorical variables that are known to be 
associated with the outcomes (Y) of interest: gender (86) and treatment (drug or placebo) in the 
OC-COPD models; smoking (87) and HIV (88) status for the LHMP models. 
By their nature, many of the variables (genera or OTUs) in microbiomes are highly 
correlated with each other. This correlation makes including all variables in the regression 
redundant and necessitates the use of the lasso or other penalty. During the maximal likelihood 
estimation of the β, B, and b coefficients, the lasso penalty is added to the log-likelihood 
approximation. The penalty parameter λ performs variable selection by forcing the smaller β and 
B coefficients to equal zero. All of the B values of one categorical variable are penalized 
together with a grouped Lasso penalty adapted from (89). Thus, either all possible statuses are 
included in the model, or none are included. For example, the LHMP smoking status 'current', 
'former', and 'never' result in two dummy variables, one for 'current' and one for 'former'. The B 
coefficients for both dummy variables are either reduced to zero or included in the model. By 
increasing λ, more of the β and B coefficients will be forced to zero. It is important to note that 
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only the fixed effects coefficients are subject to the lasso penalty. Random effects are included in 
the model regardless of the size of λ. 
We determined the optimal lasso penalty term (λ) for each model by scanning between 0 
and 200 (by increments of 1) using the R package glmmLasso version 1.3.3 (90). The model 
with the lowest Bayesian Information Criteria (BIC) (90) was selected as optimal. When λ=0, if 
the Fisher matrix was not invertible (i.e. the regression could not be completed) we started the 
scan at λ=1. We considered those genera with non-zero coefficients in the model using the 
optimal penalty term to be strongly associated with the response variable. Following Groll's 
recommendation (82), we then ran a GLMM regression including only the strongly associated 
genera using the R package lme4 (91). This final regression step is related to the adaptive lasso 
penalty and is designed to compensate for the lack of oracle properties of the basic lasso penalty 
that we used here (83). These results indicate not only a strong association, but also if the 
association was positive (more microbes when the variable is high), or negative (more microbes 
when the variable is low). 
 
2.2.4 Evaluating Models 
We evaluated the fit for each of our mixed models using both the marginal and conditional R2 
coefficients of variation (92). Marginal R2 represents the percent of variation explained by the 
fixed effects while conditional R2 represents the variation explained by the entire mixed model. 
These values provide a more absolute measure of the goodness of fit for the model in question 
compared to the BIC that was used for penalty optimization. We also inspected the residual plots 
to ensure that the relationship between the microbes and clinical variables was linear. When a 
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relationship was found to be non-linear, we attempted to refit the model with a generalized 
model. 
 
2.2.5 Dichotomous Methods 
Because there is no consensus method to evaluate the association between microbiota abundance 
and a continuous variable, we compared our LassoGLMM method to the most basic 
dichotomous variable method, the Wilcoxon (or Mann-Whitney U) test (93). The Wilcoxon test 
is a non-parametric statistical test that determines if the genus tends to be more abundant in one 
group than in another based on ranks. To dichotomize our data, we divided samples into those 
above and below the sample average for the outcome of interest. 
 
2.2.6 Ethics approval and consent to participate 
Written informed consent was obtained from all participants in both studies following approval 
of human subjects’ protection protocols from review boards of the University of Pittsburgh, 
University of California San Francisco, and the University of California Los Angeles. 
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2.2.7 Availability of data 
The sequence data supporting the results of this study are available in NCBI sequence read 
archive (SRA) under accessions PRJNA308310 (OC-COPD), SRP065274 (LHMP 16S), and 
SRP040237 (LHMP ITS). The R code that was used to implement LassoGLMM is available at 
https://github.com/ghedin-lab/LassoGLMMforMicrobiomes and can be found in Appendix A. 
 
2.3 RESULTS 
2.3.1 Associations between Oral Bacteria and Laboratory Measurements 
To identify associations between the easily accessible oral bacteria and laboratory values 
measured in blood, we characterized the microbiota in 15 oral wash samples from 8 individuals 
at two different time points, 16 weeks apart. A metabolic panel of 32 measurements, including 
electrolytes and cholesterol levels, was performed at each visit. In the 15 oral washes, we found a 
total of 95 bacterial genera present in at least half the samples. Each sample was dominated by 
Streptococcus (mean: 32.2%, standard deviation: 11.6), Prevotella (mean: 12.4%, SD: 6.5), 
Rothia (mean: 10.6%, SD: 6.5), Fusobacterium (mean: 6.2%, SD: 5.0), and Veillonella (mean: 
5.6%, SD: 3.7). 
We calculated Spearman correlations between every pair of bacterial genera and blood 
metabolic profile measurement. There were 202 correlations (out of 1,425 possible) that were 
nominally significant, p < 0.05 before correcting for multiple hypotheses testing. Each clinical 
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variable was significantly correlated with 1 to 20 genera, averaging 7.5 nominally significant 
correlations. Out of the 95 genera, 75 were nominally significantly correlated with 1 to 9 of the 
clinical variables. 
The genera that had nominal significant correlations with a clinical variable were entered 
into a LassoGLMM as potential explanatory variables along with Cyclosporine/placebo 
treatment assignment and gender. All but 64 genera (out of 202) coefficients were forced to zero 
by the Lasso penalty. Coefficients that were not forced to zero are presented in Table 2.1 and are 
considered strong associations. Ten laboratory measures were associated with bacterial genera 
since their models retained non-zero coefficients (see Figure 2.2): percent neutrophils (model 
O1), blood urea nitrogen (BUN) (model O2), immunoglobulin M (IGM; model O3), partial 
pressure of oxygen (model O4), SAT (model O5), alkaline phosphatase (model O6), serum 
glutamic oxaloacetic transaminase (SGOT; model O7), serum glutamic-pyruvic transaminase 
(SGPT; model O8), cholesterol (model O9), and glucose (model O10). Of these lab measures, 
BUN, IGM, partial pressure of oxygen, SAT, and SGPT (models O2, O3, O4, O5, and O9) were 
strongly associated with all correlated bacterial genera (optimal penalty parameters of 0). For the 
remaining 5 models, the optimal λ penalty parameter ranged from 2 to 144. The higher λ penalty 
parameters eliminated some bacterial genera in all 5 models but also eliminated drug treatment 
assignment in model O10, and gender in model O9. 
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Table 2.1: Laboratory measurements and their strongly associated bacteria in OC-COPD. Bacteria that 
could not be classified to the genus level are listed at the lowest taxonomic level that could be confidently 
identified. Bacteria in bold are negatively associated with the laboratory measurement, indicating that higher 
microbial abundance is associated with lower measurement level. 
Percent Neutrophils 
(O1) 
BUN (O2) IGM (O3) Partial 
Pressure of 
Oxygen (O4) 
SAT (O5) 
Bacteroidales 
(order) 
Aerococcaceae 
(family) 
Pseudomonas Bacillus Bacillus 
S-24 (family in 
Bacteroidales order) 
Enterococcus  Pseudomonas Pseudomonas 
Clostridiaceae Streptococcus    
Oribacterium Lachnospiraceae 
(family) 
   
Oscillospira     
Ruminococcus     
Phascolactobacterium     
Succinivibrio     
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Table 2.1 Continued 
Alkaline 
Phosphatase (O6) 
SGOT (O7) SGPT (O8) Cholesterol (O9) Glucose (O10) 
Bifidobacteriaceae 
(family) 
Bacillales 
(order) 
Rothia Micrococcaceae 
(family) 
Rothia 
Weeksellaceae 
(family) 
Lachnospiraceae 
(family) 
Scardovia Porphyromonas Porphyromonas 
Gemellales (order) Moryella Clostridiales 
(order) 
Prevotella Tannerella 
Gemellaceae 
(family) 
Oribacterium Lachnospiraceae 
(family) 
Catonella Prevotella 
Granulicatella Peptostreptococcus Moryella Filifactor Gemellaceae (family) 
Lactobacillus Eikenella Oribacterium Peptostreptococcus Lactobacillus 
Eikenella Neisseria Schwartzia Mogibacteriaceae 
(family) 
Peptostreptococcaceae 
(family) 
Neisseria Cardiobacterium Succinivibrio TG-5 (member of 
Dethiosulfovibronaceae 
family) 
Peptostreptococcus 
Aggregatibacter   TM-7.3 Veillonella 
   Mycoplasma Mogibacteriaceae 
(family) 
    TG-5 (member of 
Dethiosulfovibronaceae 
family) 
    Mycoplasma 
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Figure 2.2 OC-COPD associations between laboratory measurements and bacteria identified by 
LassoGLMM. Strong associations between bacteria and A) percent neutrophils (O1), B) BUN (O2), C) IGM 
(O3), D) partial pressure of oxygen (O4) E) SAT (O5), F) alkaline phosphatase (O6), G) SGOT (O7), H) 
SGPT (O8), I) cholesterol (O9), and J) glucose (O10). Each horizontal grey line represents an individual. 
Each colored line represents a microbe. When a colored circle is located on the grey line, it is the relative 
abundance of that microbe for that subject. Perfect positive association between clinical variable and bacteria 
would be a line from the bottom-left to the top-right of the figure and would have a highly positive β 
coefficient in the LassoGLMM. Perfect negative association would be a line from the top-left to the bottom-
right of the figure and would have a highly negative β coefficient. 
 
 
 
2.3.2 Associations of Lung Bacteria and Fungi with Cytokines 
Using the LHMP dataset, we sought to identify associations between indicators of local or 
systemic inflammation and bacteria and/or fungi detected in BAL samples. We used bacterial 
and fungal surveys previously performed on 30 BAL samples from 21 individuals (4, 40). Across 
all samples 49 bacterial genera were found in at least half of the samples and 28 fungal genera 
were found in at least 10% of the samples. There were 106 correlations (out of 1,386 possible) 
that were nominally significant at p < 0.05. Each cytokine had between 2 and 9 nominally 
significant correlations with bacterial and fungal genera (average number of genera nominally 
correlated with each cytokine = 5.9). Conversely, of the 77 genera identified, 42 were nominally 
significantly correlated with 1 to 7 cytokines. 
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These bacterial and fungal genera were entered into the LassoGLMM along with HIV 
status and smoking status as potential explanatory variables. As in the oral microbiome models, 
most genera coefficients (103 out of 106) in the LHMP models were forced to zero by the Lasso-
penalty. All fungal genera coefficients were forced to zero. The 3 bacterial genera that 
maintained non-zero coefficients are presented in Table 2.2. In 16 models assessing cytokine 
associations with genera and species, all genera/species coefficients were forced to zero, which 
indicates that increases in the cytokines are best explained by HIV and/or smoking status. The 
remaining 2 models with evidence of strong genera association retained non-zero coefficients 
(see Figure 2.3). These models were: BAL interleukin receptor antagonist (IL-ra) (model L1), 
and systemic IL-ra (model L2). BAL IL-ra (model L1) had an optimal penalty parameter of 0, 
indicating that both correlated bacteria were strongly associated with BAL IL-ra; no fungi were 
nominally correlated with BAL IL-ra. Conversely, systemic IL-ra (model L2) had an optimal 
penalty parameter of 13, retaining 1 bacterial genus as strongly associated and eliminating 7 
others as well as HIV and smoking status. 
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Table 2.2: Cytokines and their strongly associated microbes in LHMP. Bacteria and fungi that could not be 
classified to the genus and species level, respectively, are listed at the lowest taxonomic level that could be 
identified. Microbes in bold are negatively associated with the cytokine, indicating that higher microbial 
abundance is associated with lower cytokine level. 
BAL IL-ra (L1) Systemic IL-ra (L2) 
Clostridia (class) Leptotrichia 
Ralstonia  
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Figure 2.3 LHMP associations between cytokines and bacteria identified by LassoGLMM. Strong 
associations between bacteria and a) BAL IL-ra (L1) and b) systemic IL-ra (L2). Each horizontal grey line 
represents a subject. Each colored line represents a microbe. When a colored circle is located on the grey line, 
it is the relative abundance of that microbe for that individual. Perfect positive association between cytokine 
and bacteria would be a line from the bottom-left to the top-right of the figure and would have a highly 
positive β coefficient in the LassoGLMM. Perfect negative association would be a line from the top-left to the 
bottom-right of the figure and would have a highly negative β coefficient. 
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2.3.3 Model Evaluation 
To evaluate our models, we used both marginal (fixed effects only) and conditional (whole 
model) coefficients of determination, or R2 (92). For models O1-O10 we had an average 
marginal R2 value of 0.44 (SD 0.32) and an average conditional R2 value of 0.90 (SD 0.14; 
Table 2.3). These R2 values demonstrate that our models explained, on average, 90% of the 
variation seen in the clinical variables and that 44% of the variation is explained by the bacteria 
that are strongly associated with the laboratory measurements, gender, and drug treatment. 
However, models O1, O4, O5, O6, and O10 were found to be over-fitting the data with 
conditional R2 greater than 0.99. Both LHMP models, L1 and L2, were also found to be over-
fitting the data with conditional R2 equal to 1.00. The residuals from the remaining models 
indicated that the models fit the data reasonably well (Figure 2.4). The most notable exception is 
in model O3, for IGM, which has large residuals whose pattern indicates a non-linear 
relationship. We attempted to fit a generalized model to these data, as well as to models O2 and 
O7, but were unable to significantly improve the fit. 
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Table 2.3: Marginal and conditional coefficients of variation (R2) for OC-COPD models and Lasso-penalized 
GLMM variants. The two-step LassoGLMM method, in columns 1 and 2, is presented here. The original 
LassoGLMM, in columns 3 and 4, omits the first step of correlation-based variable screening, adding all 
OTUs to the LassoGLMM. The GLMM with correlated genera, in columns 5 and 6, uses the correlation-
based variable screening step, adding only those variables that are correlated with the outcome to the model, 
but modifies the second step to not include the Lasso penalty. Columns for each method contain the marginal 
and conditional R2, which represent fit of the fixed effects and entire model, respectively. 
 Two-step LassoGLMM Original LassoGLMM GLMM with correlated 
genera 
 Marginal R2 Conditional 
R2 
Marginal R2 Conditional 
R2 
Marginal R2 Conditional 
R2 
BUN (O2) 0.58 0.60 No non zero coefficients All correlated variables were 
in Two-step LassoGLMM 
IGM (O3) 0.19 0.89 No non zero coefficients All correlated variables were 
in Two-step LassoGLMM 
SGOT (O7) 0.22 0.84 No non zero coefficients 0.50 0.59 
SGPT (O8) 0.44 0.75 No non zero coefficients All correlated variables were 
in Two-step LassoGLMM 
Cholesterol 
(O9) 
0.80 0.93 0.95 0.98 0.99 1.00 
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Figure 2.4 Observed vs predicted value plots evaluating the fit of the LassoGLMMs from the OC-COPD 
study. Each plot represents one LassoGLMM with non-zero coefficients that was not found to be over-fitting 
the data. The value observed (X-axis) is plotted against the value predicted by the LassoGLMM (Y-axis). 
Each point represents a sample. The red line indicates where the predicted value matches the observed value. 
For models that deviate from this line (O2, O3, and O7), we attempted to fit a generalized model but found no 
significant improvements in fit. 
 
 
 
We then compared our models with LassoGLMMs, as originally described by Groll (82, 
90), leaving out our first-step of variable screening, and to non-penalized GLMMs that include 
all correlated genera that passed variable screening, thus modifying the second step of our two-
step LassoGLMM method. The GLMM with all correlated genera can also be thought of as a 
two-step LassoGLMM with a lambda penalty parameter of 0. When 0 is the optimal lambda for 
the two-step LassoGLMM method presented here, these two models are identical. The marginal 
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and conditional R2 values for each model are included in Table 2.3. With the notable exception 
of model O9, we found that our two-step model performed at least as well as the original 
LassoGLMM without a variable screening step and applying a non-penalized GLMM after a 
variable screening step. By including both the variable screening step and the lasso penalty, our 
two-step method successfully found associations that would have been missed when the original 
LassoGLMM retained no non-zero coefficients. It is also capable of finding identical models to 
the non-penalized GLMM with all correlated variables. 
 
2.3.4 Comparison to Categorical Methods 
To evaluate the performance of our method as compared to the categorical methods that are used 
most frequently in the microbiome field, we dichotomized the continuous variables based on 
their average values; we then compared the microbiota between the two groups using a Wilcoxon 
test (93). 
For the ten models with non-zero coefficients in the OC-COPD (models O1-O10), the 
Wilcoxon tests found between 1 and 12 (average 5.4) bacterial genera to be differentially 
abundant between above- and below-average outcome groups, before correcting for the large 
number of tests (Figure 2.5). For each of the 2 cytokines with non-zero coefficients in the 
LHMP (models L1-L2), the Wilcoxon test found 2 bacterial and 1 fungal genera to be 
differentially abundant between above- and below-average cytokine groups (Figure 2.6). When 
each outcome or cytokine was corrected for multiple hypotheses testing using the Benjamini-
Hochberg false discovery rate (94), no genera were significantly differentially abundant. Before 
multiple hypotheses testing correction, the 60 significantly different genera across all 12 models 
 51 
showed 52% overlap with the 67 genera identified as strongly associated with the outcome by 
the LassoGLMM. With one exception (Leptotricia in model L2), all genera identified by the 
LassoGLMM had a Wilcoxon test p-value no greater than 0.23, indicating that there is a 
difference between the samples with high and low outcomes that may be identified by a test with 
more statistical power or a much larger sample size. 
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Figure 2.5 Wilcoxon P-values compared to LassoGLMM β coefficients for OC-COPD study. Each plot 
represents one LassoGLMM with non-zero coefficients. For each bacterial genus, the Wilcoxon P-value 
(before adjustment for multiple hypotheses testing) is plotted on the X-axis and the LassoGLMM β coefficient 
is plotted on the Y-axis. Most β coefficients are equal to zero. The dashed vertical line indicates nominal 
significance based on a Wilcoxon P-value of 0.05. 
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Figure 2.6 Wilcoxon P-values compared to LassoGLMM β coefficients for LHMP study. Each plot represents 
one LassoGLMM with non-zero coefficients. For each bacterial or fungal genus, the Wilcoxon P-value (before 
adjustment for multiple hypotheses testing) is plotted on the X-axis and the LassoGLMM β coefficient is 
plotted on the Y-axis. Most β coefficients are equal to 0; those that are not are labeled with their lowest 
taxonomic assignment appearing horizontally. The dashed vertical line indicates nominal significance based 
on a Wilcoxon P-value of 0.05. The nominally significant genera that have a β coefficient of 0 are labeled with 
their lowest taxonomic assignment appearing vertically. 
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2.4 DISCUSSION 
We applied the LassoGLMM to two mucosal microbiome datasets to analyze the relationship of 
microbes and their abundances to continuous clinical variables with repeated measurements. We 
were able to computationally identify a number of associations between microbes and continuous 
clinical variables, including standard blood chemistries. To date, there is no other established 
approach to relate repeatedly measured continuous outcomes to microbes and their abundances 
and thus this method represents an important addition to the field. 
Traditionally, associations between microbial abundance and continuous outcomes, with 
repeated measures or not, have been built on an arbitrary grouping of samples derived from the 
values found within the study itself. Often samples are grouped by whether their measurement is 
above or below the study average, as we did in our comparison of the LassoGLMM to the 
Wilcoxon test. The study-dependent splitting of a variable limits reproducibility and ignores 
natural variation in the larger population. Any association between microbial abundance and a 
repeated clinical measurement found by this type of test ignores the fact that repeated samples 
are not independent of each other. This limitation may explain why there was minimal overlap 
between the genera identified by the LassoGLMMs and the Wilcoxon test. 
Repeated measurements taken in the clinic, such as ours, break a number of assumptions 
that are common among statistical tests, even those developed specifically for microbiome 
studies. Multivariate Association with Linear Models (MaAsLin) was recently developed to 
simultaneously find associations between microbes and multiple clinical outcomes, including 
continuous variables, through variable selection and linear modeling (95). These models make 
the assumption that all samples are independent and do not allow for the complex covariance 
structure that accompanies repeated measurements. The two-part zero-inflated Beta regression 
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model with random effects (ZIBR) is designed to handle repeated measurements through the use 
of random effects, but assumes that all subjects will have samples taken at the same time points 
with no missing measurements (96). With so many points of failure, from a missed appointment 
to failed amplification and sequencing, real-world clinical datasets rarely contain all time points 
for all subjects. Both MaAsLin and ZIBR use microbial abundances as the response variables 
and clinical measurements as the explanatory variables. This set up does not allow for 
correlations or interactions between microbial abundances beyond compositional effects. 
One of the advantages of the LassoGLMM is the ability to find associations in small 
sample sizes. The statistical power of GLMMs is best calculated by simulations that account for 
the impact of the random effects (97), which are largely unknown in microbiome studies. Despite 
the lack of a power analysis, we were able to find associations in our studies, both of which have 
small sample sizes by any standard. However, many of the early microbiome studies also had 
small samples sizes and, with their data accessible in public repositories, are available for re-
analysis with newly developed tools such as the LassoGLMM. 
Another added advantage of the LassoGLMM is the ability to account for correlations 
between genera, which may be indicative of biological interactions. Too many interactions or 
correlations between genera can be problematic for the lasso penalty, as it may discard a 
biologically important genus while retaining a non-zero coefficient for a correlated but less 
biologically important genus. The number of interactions can be mitigated by reducing the 
number of genera entered into the LassoGLMM with a variable screening step. The “choices” 
that the lasso penalty makes highlight the need to study the relationships between the genera in 
addition to their relationships with the outcome variable. Genera whose coefficients are pushed 
to zero may be chemically or physically interacting with genera whose coefficients are non-zero. 
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Or, if negatively correlated with each other, may be performing the same function. This 
redundancy may stem from bacterial interactions or from competition to fill the same niche. 
Biological interactions between genera within a microbiome represent an area of active research 
and in the meantime, methods such as LassoGLMM that can account for these uncharacterized 
interactions should be better able to determine associations than methods that ignore them. 
A separate area of active research that will likely lead to improved discovery of 
associations between clinical variables and the microbiome is penalization parameters. Here we 
used a single parameter lasso penalty, applying the same penalty to both the continuous and 
discrete fixed effects. In graphical models with combinations of continuous and discrete 
variables, separate penalty parameters have been shown to improve accuracy in graphical models 
(98), and may have a similar impact on other regression models. 
 
2.5 CONCLUSIONS 
The potential applications of the LassoGLMM are multiple and go beyond what we have used it 
for here. We took advantage of the ability to account for potentially confounding categorical 
variables, treatment assignment and gender in OC-COPD, and HIV status and smoking status in 
LHMP. This ability can be used to account for attributes that are known or suspected to influence 
the outcome variable, including host genotype. We made use of the ability to analyze repeated 
measurements from the same individual, over two time points in OC-COPD, and in two lung 
locations (right and left lungs were sampled separately) in the LHMP. The method can 
accommodate any number of repeated measurements, including long-term longitudinal studies, 
 57 
even when the number of measurements per individual is not identical. The inclusion of the 
individual as a random effect also accounts for an uneven number of observations per subject, a 
common issue in the clinic where study participants can be followed for different lengths of time, 
can be “lost to follow-up”, may die, or may drop out of the study. The generalized nature of the 
LassoGLMM also allows for the analysis of variables that do not follow a normal distribution, 
including time-to-event and categorical outcomes. The lasso penalty allows for variable selection 
to select the strongest genera associations but the selection criteria may be influenced by the 
correlations between microbes inherent in relative abundance data. However, the LassoGLMM is 
not limited to relative abundance data and when a consensus is reached about the optimal 
normalization methods for microbiome data, this method will be able to handle that data and 
improve performance.   
We have demonstrated that the lasso-penalized generalized linear mixed model can be 
applied to microbiome studies with continuous outcomes and repeated measures. This model 
works well with both 16S rRNA gene surveys and more complicated 16S/ITS combination 
studies. The method combines the well-established lasso penalty to account for the large number 
of variables with the mixed model to account for repeated sampling—including longitudinal 
studies—and other variables that are known to be associated with the outcome. The power of this 
method lies not only in its ability to identify known associations between microbes and 
continuous clinical variables, but in its ability to identify novel associations that can be used to 
test new potential biomarkers.  
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3.0  INFERRED CROSS-DOMAIN INTERACTIONS IN THE LUNG AND SKIN 
MICROBIOMES4 
 
3.1 INTRODUCTION 
Determining networks of microbial interactions that affect the fitness of individual species is 
relevant for the functional characterization of a microbial community. These interactions can 
vary across time and space, depending on both abiotic and biotic factors. Common abiotic factors 
include oxygen, temperature and pH, while biotic factors can include the presence or absence of 
other microbes. The ability to predict biological interactions between microbes based on next-
generation sequencing data, particularly from targeted amplicon sequencing (TAS), has been a 
topic of increasing interest with the development of multiple statistical tools for inferring 
networks (99–101). Within a microbiome, interactions can be informative at both the species and 
at the community levels. 
At the individual species level, knowledge of interactions could provide information 
relevant to the growth or the targeting of the microbe. Interactions between a microbe that is 
                                                 
4 Paper in preparation 
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considered un-culturable and a well-studied microbe that can be grown in culture would increase 
the chances of successfully growing the un-culturable microbe in the lab either through co-
culture, spent media, or the inclusion of metabolites secreted by the well-studied organism. Co-
culture has, for example, enabled the cultivation and sequencing of a member of the candidate 
division TM7, called TM7x, from the human oral microbiome (102). TM7x is now known to be 
an obligate epibiont of Actinomyces odontolyticus and cannot be cultured without it or a related 
basibiont. On the other end of the spectrum, interactions between a drug-resistant pathogen and 
drug-susceptible microbes can lead to new treatment strategies targeting the easier to kill 
microbes to render the pathogen harmless. Fungal pathogens that are notoriously harder to target 
than bacteria due to their closer evolutionary relationship with their human hosts may be 
particularly suited for this method of treatment (103). 
At the community level, an interaction network reveals useful information about the 
structure and stability of the community. The topology or graph structure of an interaction 
network can indicate evolutionary pressures on the community (104). This phenomenon is seen 
in “hubs,” or highly connected nodes, in any ecological interaction graph can indicate keystone 
species that have a large impact on their environment and many direct and indirect interactions 
with other species in the community (often despite being present in low abundance) (105). One 
such keystone species has been identified in the human gut microbiome, Ruminococcus bromii, 
by its superior ability to degrade resistant starches and release nutrients to the direct or indirect 
benefit of the other members of the microbiome (106). 
An alternative topography would be disjointed cluster graphs, where each cluster 
represents an ecological niche being filled. Such niche separation can be seen in the separation of 
the lung microbiome of SHIV-infected cynomolgous macaques into bacteria enriched in the 
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animals that developed chronic obstructive pulmonary disease (COPD) and bacteria that are 
enriched in the animals that retained normal lung function (107)5. This network demonstrated 
negative associations between two large groups of OTUs and positive associations within each 
group (Figure 3.1A); singleton OTUs (i.e. not associated with any other OTU) were removed. In 
the first group, we saw OTUs belonging to the genera that were enriched in animals that 
developed COPD including Fusobacterium, Prevotella, Veillonella, Neisseria, and 
Porphyromonas (Figure 3.1B). In the second group, we saw OTUs in the genera identified as 
enriched in non-COPD animals including Uruburuella and Flavobacterium (Figure 3.1B). Other 
OTUs in this group that were not identified by the other methods belonged to genera including 
Kinesporia, Enterococcus, and Vibrio. Most interestingly, OTUs belonging to the Streptococcus 
genus were found in both groups, highlighting its importance within both COPD and non-COPD 
bacterial communities. The separation of the two groups showed the difference in community 
composition that accompanied the development of COPD. The negative correlations between 
members of the two groups emphasize how shifts in one species can impact multiple other 
species, potentially resulting in disease. 
 
 
                                                 
5 This paragraph extracted from paper published in Microbiome as “Longitudinal analysis of the lung 
microbiota of cynomolgous macaques during long-term SHIV infection” (107). 
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Figure 3.1 SPIEC-EASI Network for Cynomolgous Monkeys with SHIV Infection. The ecological correlation 
network shows two groups of OTUs that are negatively correlated with each other. One group includes OTUs 
identified as enriched in COPD animals and the other includes OTUs enriched in non-COPD animals. Each 
node represents an OTU and is colored by its assigned taxonomy. Green edges represent positive correlation 
between OTUs and red represent negative correlation. In the insert, negative edges have been removed to 
show that the two groups have no positive correlations with each other. Figure from (107). 
 
 
 
Evidence of community stability, or robustness to perturbation, can be seen in the level of 
connectedness of these interaction networks. If the interaction network is considered to be a 
system for passing metabolites as messages, and the network has a scale-free topology, then a 
more connected network is a more stable network (100, 108). Network and community stability 
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become important in microbiomes when species are wiped out by antibiotics, or by other means 
(109). 
While many methods have been developed to infer interactions between microbes based 
on TAS, these inferences are often based on co-occurrence or correlations (99, 101, 110, 111). 
These methods were developed on (and, to our knowledge, have only been applied to) bacterial 
communities. Bacterial microbiome studies rely on TAS of the gene encoding the 16S subunit of 
the ribosomal RNA gene (16S rRNA gene). By targeting the 16S rRNA gene sequence, these 
studies ignore other important components of the community, such as viruses and eukaryotes, 
including fungi. Although present at significantly lower levels than bacteria, fungi play an 
important role in the microbial community and interactions between individual fungi and 
bacteria are well-documented (99, 112, 113), making these interactions of relevance for further 
study (72).  
Here we present a statistically sound method for investigating cross-domain interactions, 
apply this method to the human lung and skin microbial communities, and validate three 
predicted interactions, including two cross-domain interactions. Sparse InversE Covariance 
estimation for Ecological Association Inference (SPIEC-EASI, pronounced “speak-easy”) 
identifies networks of interactions based on TAS data from a single domain (104). The included 
centered log ratio (CLR) transformation was designed specifically for the compositional nature 
of the relative abundances. By applying the CLR transformation separately to the independent 
compositions of bacteria and fungi, we maintain the statistically sound properties of the 
transformation. By using independent TAS studies of the 16S rRNA and Internal Transcribed 
Spacer (ITS) from the same samples, SPIEC-EASI is able to infer both within domain and cross-
domain interactions. 
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In order to identify interactions that may be exploited in the future, we applied SPIEC-
EASI to two microbiome studies that include both bacterial 16S rRNA and fungal ITS sequence 
data: the lung microbiome from the Pittsburgh cohort of the Lung HIV Microbiome Project (4, 
40), and the skin microbiome (114, 115). We then validated by co-culture a subset of three 
predicted interactions from the skin microbiome, including two cross-domain interactions. 
3.2 RESULTS 
To highlight the variety and impact of cross-domain interactions on community stability, we 
analyzed the interaction networks of two microbiome communities. The first community was the 
lung microbiome from the Pittsburgh cohort of the Lung HIV Microbiome Project (4, 40). The 
cohort included both HIV-positive and HIV-negative individuals as well as individuals with 
normal lung function or chronic obstructive pulmonary disease (COPD). The cohort consisted of 
25 individuals with a total of 35 bronchoalveolar lavage (BAL) samples. The second community 
was the skin microbiome from a National Human Genome Research Institute study (114, 115). 
This cohort consisted of 10 healthy individuals from whom 382 skin swab or nail clipping 
samples from 14 body sites were obtained. The sites were classified by the body region from 
which they originate (head, torso, arm, or foot) and also by what type of environment was 
present at the site (dry, moist, or sebaceous). Using SPIEC-EASI, we created three ecological 
networks for each microbiome: one of bacteria only, one of fungi only, and one of the 
combination of bacteria and fungi. We compared the connectedness, distances between nodes, 
and robustness of the three networks.  
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3.2.1 Lung Microbiome 
In the “bacteria only” network derived from the lung microbiome dataset, we observed a network 
with a dense central cluster of well-connected nodes and several less-connected nodes on the 
periphery (Figure 3.2A). The majority of the operational taxonomic units (OTUs) (99.01%) 
created a single connected component with only 3 out of 302 (0.99%) OTUs with no connections 
to the main graph. This topography led to an average degree of nodes (number of adjacent edges) 
of 15.75 (SD: 10.70). There was also a high degree of assortativity, or clustering, by phyla, with 
the nominal assortativity coefficient (116) of the network by phyla measured at 0.518. Even the 
unclassified bacterial OTUs clustered together, with 61/66 (92.94%) forming a connected 
subcomponent with distances of no more than 3 edges between nodes. Overall, the network was 
highly connected, with an average normalized node betweenness centrality (a measure of the 
number of shortest paths through the node, where a lower number means a more connected 
network) of 0.007 (SD 0.010). 
In the “fungi only” network of the lung microbiome, we saw a largely banded network 
that appears sparser than the bacteria only network (Figure 3.2B). This network contained one 
large connected component (83.33% of OTUs), 4 dyads (8.33%), and 8 singletons (8.33%). 
There was minimal assortativity within this network, with the nominal assortativity coefficient 
measuring 0.216. The low assortativity may be due to the low average degree of nodes (3.46; 
SD: 2.35). Yet the network remained well connected with an average normalized node 
betweenness centrality of 0.027 (SD: 0.032). 
Surprisingly, the combined bacteria and fungi analysis of the lung microbiome provided a 
network that appeared more connected than either bacteria or fungi alone (Figure 3.2C). Only 
one fungal OTU out of 370 nodes (0.27%) remained outside the connected component. This 
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OTU was identified as Candida dubliniesis and in the “fungi only” network it was only 
connected to the fungus Plicaturopsis crispa, which did not appear in the combined dataset. The 
edges across domains, between bacteria and fungi, resulted in a higher average degree of the 
nodes (16.12; SD: 9.78) than either the “bacteria only” or “fungi only” networks. Assortativity of 
the combined network was somewhere between the “bacteria only” and “fungi only” networks, 
with the nominal assortativity coefficient measuring 0.320, and the bacteria forming a central 
cluster and the fungi being more peripheral. Within the central cluster there was no distinct 
clustering as there was in the “bacteria only” network. Overall, the network was very highly 
connected with an average normalized node betweenness centrally of 0.005 (SD: 0.005). 
 66 
 
 
Figure 3.2 Lung microbiome networks. Networks inferred for the lung microbiome based on (A) bacteria only, (B) fungi only, and (C) combination of 
bacteria and fungi. In all three networks, bacterial nodes are circles and fungal nodes are squares. Each node is colored by phyla. Edges between nodes 
represented a predicted interaction, either positive or negative. 
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We then compared the combined network to the domain specific networks. We found that 
the distances between given node pairs were significantly shorter in the combined network 
(mean: 2.588; SD: 0.734 between bacterial nodes and mean: 3.604; SD: 1.508 between fungal 
nodes) than in the “bacteria only” (mean: 3.176; SD: 1.094, Welch t-test p<0.0001) or “fungi 
only” (mean: 4.549; SD: 2.203; Welch t-test p<0.0001) networks. Similarly, the node 
betweenness centrality for the bacterial nodes in the combined network was significantly lower 
than in the “bacteria only” network (Welch t-test p=0.003) while the decrease in node 
betweenness centrality for fungal nodes approached significance (Welch t-test p=0.057). This 
increased connectivity resulted in a larger percentage of nodes contained in the connected 
component (99.73% for the combined network vs 99.01% in “bacteria only” and 83.33% in 
“fungi only”). We measured the robustness of the networks by sequentially removing nodes and 
measuring the percent of the remaining nodes in the largest connected component (Figure 3.3). 
Nodes were removed in order of decreasing betweenness (Figure 3.3A), in order of decreasing 
degree (Figure 3.3B), or at random (Figure 3.3C), and in each case, the combined network was 
found to be slightly more robust than the “bacteria only” and greatly more robust than the “fungi 
only” network.  
To determine the influence of HIV infection and COPD on our network, we examined the 
nodes present in only HIV-infected or HIV-uninfected individuals and those nodes present in 
only individuals that were COPD positive or those with normal lung function. For HIV status, 17 
fungal nodes were present only in HIV-infected individuals while 1 bacterial and 5 fungal nodes 
were present only in HIV-uninfected individuals. All single HIV infection status nodes occurred 
around the periphery of the combined network and had a significantly lower average normalized 
node betweenness centrality (HIV-infected and HIV-uninfected exclusive nodes: 0.004, SD: 
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0.003 vs non-exclusive nodes: 0.005, SD: 0.005, Welch t-test p=0.011). For COPD status, 7 
fungal nodes were present only in individuals with COPD while 8 bacterial and 10 fungal nodes 
were present only in individuals with normal lung function. Similar to the single HIV infection 
status nodes, the single COPD status nodes were located on the periphery with significantly 
lower average normalized node betweenness centrality (COPD positive and normal lung function 
exclusive nodes: 0.003, SD: 0.003 vs non-exclusive nodes: 0.005, SD: 0.004, Welch t-test 
p=0.006). All of these nodes were therefore unlikely to impact the connectedness or robustness 
of the network. We then examined each of the 4 “neighborhoods” surrounding the exclusive 
nodes, which consist of the exclusive nodes and their immediate neighbors (Figure 3.4). 
Comparing these neighborhoods, we saw that the HIV-infected neighborhood, containing 17 
single-status nodes and 51 adjacent nodes, was larger and more connected than the HIV-
uninfected neighborhood which had 6 single-status nodes and 32 adjacent nodes (Figure 3.4A). 
In contrast, it was the normal lung function neighborhood that was larger and more connected 
than the COPD positive neighborhood, 17 normal lung function nodes and 51 adjacent nodes 
compared to 7 COPD positive nodes and 33 adjacent nodes (Figure 3.4B). 
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Figure 3.3 Robustness curves for all networks. Robustness of a network is measured by sequentially removing 
nodes based on the node’s (A) betweenness, (B) degree, or (C) randomly selected and measuring the 
percentage of nodes that remain in the central connected component. Measurement of robustness was 
performed for each of our 6 networks and the results are plotted here with the percentage of nodes removed 
on the X axis and the percentage of remaining nodes in the central connected component on the Y axis. Each 
network is represented by a line on this graph. A fully connected, completely robust network would be a 
horizontal line at 1; the closer a line is to this horizontal, the more robust the network is. 
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Figure 3.4 Lung microbiome neighborhoods for HIV infection and COPD status. Bacterial and fungal OTUs 
that occurred exclusively in (A) HIV-infected or HIV-uninfected, or (B) COPD negative or COPD positive 
samples and their adjacent nodes were isolated from the combined lung microbiome network (Figure 3.2C). 
Round nodes represent bacteria and square nodes represent fungi; green edges represent positive 
interactions and red edges represent negative interactions. The single-status nodes are colored orange if they 
are exclusive to the negative status and blue if they are exclusive to the positive status; nodes that are not 
exclusive are black or dark grey. Single-status nodes are labeled with their genus or species. 
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3.2.2 Skin Microbiome 
In the “bacteria only” network of the skin microbiome, we saw a dense network similar to the 
“bacteria only” network in the lung microbiome (Figure 3.5A). The majority of OTUs, 130 out 
of 153 (84.97%), were in one large connected component, leaving 18 (11.76%) in a small 
connected component, and 5 (3.27%) singletons completely disconnected from the rest of the 
network. The resulting graph had an average degree of the nodes of 11.37 (SD: 7.63). Unlike the 
lung microbiome “bacteria only” network, there was minimal assortativity in the “bacteria only” 
network of the skin microbiome to the point of a negative nominal assortativity coefficient of -
0.017. However, the network remained highly connected with a normalized betweenness 
centrality of 0.011 (SD: 0.021). 
In the “fungi only” network of the skin microbiome, the network consisted of one large 
connected component containing 79 out of 94 (84.04%) nodes, a quintet (5.32%), a dyad 
(2.13%), and 8 singletons (8.51%) (Figure 3.5B). This topography resulted in a lower average 
degree of the nodes of 7.51 (SD: 6.40). Similar to the “fungi only” network for the lung 
microbiome, there was no obvious visual assortativity among the fungal phyla in the skin 
microbiome, although the nominal assortativity coefficient measured 0.438. Yet the network 
remained highly connected with a normalized node betweenness centrality of 0.014 (SD: 0.026). 
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Figure 3.5 Skin microbiome networks. Networks inferred for the skin microbiome based on (A) bacteria only, (B) fungi only, and (C) combination of 
bacteria and fungi. In all three networks, bacterial nodes are circles and fungal nodes are squares. Each node is colored by phyla. Edges between nodes 
represented a predicted interaction, either positive or negative. 
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In the combined bacteria and fungi network of the skin microbiome, we saw our only 
fully connected network, indicating the inclusion of many cross-domain edges (Figure 3.5C). 
This topography resulted in a very high average degree of the nodes of 40.03 (SD: 13.77), and a 
low normalized node betweenness centrality of 0.006 (SD: 0.005). Assortativity remained 
relatively low in the combined network, with the nominal assortativity coefficient measuring 
0.170, although visualization hinted at a separation between the bacteria and fungi. 
When we compared the combined network to the domain specific networks, we found 
that it was the most connected of the three networks. A larger percentage of the nodes were 
contained in the connected component, but the node betweennness centrality was not 
significantly lower than the “bacteria only” (Welch t-test p=0.111) even though it was 
significantly lower than the “fungi only” networks (Welch t-test p=0.004). The reduction in 
distance between two connected nodes was highly significant in both the bacteria (from 3.05; 
SD: 1.31 in the “bacteria only” network to 2.10; SD: 0.67; Welch t-test p<0.0001) and fungi 
(from 2.75; SD: 1.23 in the “fungi only” network to 2.12; SD: 0.73; Welch t-test p<0.0001). The 
combined network for the skin microbiome was the most robust network of our study, regardless 
of the method used to select nodes for removal. The combined network was much more robust 
than either the “bacteria only” or “fungi only” networks for the skin microbiome and even more 
robust than the combined network for the lung microbiome (Figure 3.3A-3.3C).  
To rule out any impact of the wide variety of skin sampling sites, we looked at nodes by 
sampling region (head, torso, arm, and foot) and by location physiology (dry, moist, and 
sebaceous). All nodes were found in at least 3 of the regions and across all physiologies, so 
sampling site had no impact on the overall network or the interactions within.   
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3.2.3 Co-culture Validation 
To validate interactions across domains without support in the literature, we looked for a 
maximal clique (a fully connected component to which no other nodes can be added and still be 
fully connected) in the combined network of the skin microbiome that was limited to 3 nodes 
(281 cliques) and included at least 1 bacterium and 1 fungus (143 cliques). We further limited 
ourselves to medically relevant fungi that could be commercially obtained and to bacteria that 
could be identified to the species level and were commercially available. Seven cliques 
remained. Of these remaining cliques, 1 clique contained non-pathogenic microbes that grow on 
brain heart infusion (BHI). This clique contained a positive predicted interaction between the 
fungus Emericella nidulans (also called Aspergillus nidulans) and the bacterium 
Propionibacterium acnes. The third member of the clique was Rothia dentocariosa, which was 
predicted to have negative interactions with both E. nidulans and P. acnes (Figure 3.6A).  
To measure growth, we established and compared growth curves for each bacterial 
species under uniform conditions (see methods), in pairs, and finally as a trio. Of the three 
predicted interactions being tested in duo-cultures, we were able to confirm two. As predicted, P. 
acnes appeared to grow better for the first 72 hours when in the presence of E. nidulans than 
when grown in monoculture. However, a Kolmogorov-Smirnov (KS) test revealed that the two 
growth curves were not significantly different (p=0.211; Figure 3.6B). As also predicted, R. 
dentocariosa grew significantly worse in the presence of E. nidulans than when grown in 
monoculture (KS p=0.003; Figure 3.6C). While a negative interaction was predicted between P. 
acnes and R. dentocariosa, the growth curve of the duo-culture was slightly above that of R. 
dentocariosa in monoculture or the sum of the two monocultures, but it was not significantly 
greater (KS p=0.299 and p=0.591, respectively; Figure 3.6D). Finally, we looked at bacterial 
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growth in a tri-culture with all three microbes. The overall effects were not predicted explicitly 
by the network, but we expected a negative effect on bacterial growth due to the greater number 
of negative interactions. The bacterial growth of the tri-culture curve could not be distinguished 
from either R. dentocariosa or P. acnes in monoculture (KS p=0.228 and p=0.925, respectively; 
Figure 3.6E). However, our bacterial growth curve measurements could not distinguish between 
R. dentocariosa and P. acnes, meaning that this curve could represent growth of one species and 
the complete death of the other. 
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Figure 3.6 Growth curves for co-culture validation experiment. A maximal clique (A) was identified in the 
combined skin microbiome network that included a positive interaction (shown in green) between Emericella 
nidulans and Propionibacterium acnes and negative interactions (shown in red) between Rothia dentocariosa 
and both E. nidulans and P. acnes. The interaction edges are labeled with the optimal covariance between the 
two nodes. The microbes were grown in pairs and a trio, and the growth curves for the bacteria were 
compared to when they were grown in monoculture. Growth curves are based on the average of 3 biological 
replicates and the vertical lines indicate their standard deviations. (B) P. acnes grown with E. nidulans (red 
line) or alone (purple line); (C) R. dentocariosa grown with E. nidulans (green line) or alone (blue line); (D) R. 
dentocariosa grown with P. acnes (orange line) or alone (blue line); the sum of R. dentocariosa and P. acnes 
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monocultures is represented by the dashed orange line; (E) trio of all three organisms grown together (pink 
line) compared to R. dentocariosa alone (blue line) or P. acnes alone (pink line). 
3.3 DISCUSSION 
Based on SPIEC-EASI, we modified the CLR to investigate cross-domain interactions then 
applied this method to create three ecological networks each for the lung and skin microbiomes: 
one of bacteria only, one of fungi only, and one of the combination of bacteria and fungi. In the 
lung microbiome, we found all three networks to be well connected but the network that included 
both bacteria and fungi was the most well connected and robust. From this network we were able 
to isolate interactions specific to HIV infection and COPD. We found that the HIV-infected 
neighborhood was larger and more connected than the HIV-uninfected neighborhood, in part due 
to a higher number of exclusive nodes and to an increase in the number of fungal taxa in the 
lungs. If the exclusive nodes and their interactions build over time, it could be indicative of a 
fungal succession that occurs following HIV infection. In contrast, the neighborhood associated 
with normal lung function was more connected than the COPD neighborhood, indicating that 
several core interactions are lost when COPD develops.    
Similar to the lung microbiome, all three ecological networks from the skin microbiome 
were well connected, but the network that included both the bacteria and fungi was the most 
connected and robust. From this network, we isolated a clique containing one model fungus and 
two common bacteria that could be cultured under the same conditions. By co-culturing the 
bacteria and fungus we saw growth curves in line with two of the three predicted interactions: a 
positive interaction between E. nidulans and P. acnes, and a negative interaction between E. 
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nidulans and R. dentocariosa. This represents the largest culture-based validation to date of 
microbial interactions predicted computationally. 
In both microbiome communities, we saw increased connectivity in the combined 
networks. This increase in connectivity indicates cross-domain interactions between the bacteria 
and fungi. Cross-domain interactions made up 135 out of 2982 (4.53%) of all interactions in the 
lung microbiome and 480 out of 2292 (20.94%) of all interactions in the skin microbiome. The 
greater percentage of cross-domain interactions in the skin may be driven by the higher biomass 
located there or by the greater overlap of OTUs between the skin samples. 
While many interactions have been previously identified between bacteria and common 
fungi, such as Candida, they appear to be ecosystem dependent. In supragingival plaque, 
Candida albicans interacts with Streptococcus to form “corncob” structures (117). In contrast, in 
the human gut microbiome, Candida correlates with Prevotella and Ruminoccus species (113) 
with no correlation with Streptococcus. Although Candida species and all 3 of these bacterial 
genera were present in the lung and skin microbiomes, we did not see evidence for these 
interactions in our datasets. Instead, we observed interactions in the lung microbiome between 
Candida tropicalis and Capnocytophaga, Veillonella, and Streptococcus and between Candida 
parapsilosis and Neisseria and an unclassifiable member of the Bacteroidales order. In the skin 
microbiome, the only Candida species detected, Candida parapsilosis, had 8 cross-domain 
interactions (out of 18 interactions): Rothia dentocariosa, Propionibacterium granulosum, 
Streptococcus spp, and 5 unclassified OTUs. Because of the ecosystem specific interactions seen 
elsewhere, it is not surprising that we identified different patterns of Candida-bacteria 
interactions in the lung and skin microbiomes. 
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Candida and other model fungi, including E. nidulans, have been studied in co-culture 
with bacteria in the laboratory to induce properties not produced in mono-cultures. Direct contact 
between C. albicans and Fusobacterium nucleatum, both oral microbiome commensals, leads to 
mutual attenuation of virulence, preventing C. albicans from transitioning to its pathogenic 
hyphal phase (118). Direct contact with the bacterium Streptomyctes hygroscopicus is required 
for E. nidulans to produce secondary metabolites, including polyketide synthase, often seen in 
nature, but not in the laboratory (119). These two model organisms highlight the variety of cross-
domain interactions that can and do occur in microbiomes. However, most co-culture 
experiments, including those between C. albicans and F. nucleatum or between E. nidulans and 
S. hygroscopicus, originate from the knowledge that the common fungus grows in physical 
proximity to the bacteria rather than from computationally-predicted community ecological 
networks.  
Interactions between bacteria and less common fungal species are more difficult to 
identify. Similar to the notion that only 1% of known bacteria can be grown in the laboratory 
(73, 74), fewer than 17% of known fungi are considered culturable, representing fewer than 1% 
of the estimated global fungal species (75). The global species estimate is based largely on the 
ratio of vascular plants to fungi, which demonstrates how little is known about fungal diversity. 
If a fungus is unknown or understudied, then little to nothing is known about its cross-domain 
interactions. 
We have shown here that cross-domain interactions can be inferred computationally and 
in a statistically sound manner using SPIEC-EASI. As validation of some of the inferred 
interactions, we co-cultured a small subset of microbes with positive and negative predicted 
interactions. We considered this co-culture experiment to be a basic proof of principle; therefore, 
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it had severe limitations. We limited ourselves to commercially available strains of aerobic and 
aerotolerant species, which may or may not be representative of what was present on an 
individual’s skin. The choices we made in setting up our experiments represent an 
oversimplification of the community: we seeded the cultures with approximately equal numbers 
of bacteria and an order of magnitude lower of fungi, which was not representative of their 
relative abundance in our samples. We also seeded all three organisms at the same time, but it is 
highly likely that colonization occurs in stages and not concurrently. We made no attempt to 
identify mechanisms such as shared metabolites and did not include or attempt to mimic the 
human skin on which these microbes would normally interact. Despite these limitations, the co-
culture serves as a first step towards validating the interactions inferred with SPIEC-EASI and do 
indeed demonstrate the positive or negative effects these microbes have on each other’s growth. 
These limitations highlight how complicated microbial interactions are likely to be and 
demonstrate how a tool such as SPIEC-EASI can help infer some of these interactions and 
provide biological insight. 
 In summary, we have devised a statistically sound method for predicting cross-
domain interactions, applied this method to two human-associated microbiome datasets, and 
validated a subset of the predicted interactions. From these results, we can conclude that limiting 
studies of ecological interaction networks to a single domain fails to reveal the entirety and 
robustness of the network. In the future, we expect to see this approach being used to incorporate 
protists, archaea, and even viruses as well as an increase in culture-based validations and 
searches for interaction mechanisms of computationally predicted interactions.   
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3.4 METHODS 
3.4.1 Adapting SPIEC-EASI for Two Domains 
We adapted the SPIEC-EASI method to analyze microbiome networks across multiple microbial 
domains (104). The tables of absolute abundance of bacteria and fungi OTUs are stored in 
matrices  and , where  and 
 denote the d- and p-length row vectors of counts from the jth sample, 
and denotes the set of natural numbers. We define the total cumulative counts for each 
domain as M(j) =  and N(j) = . 
In a standard sequencing experiment, the true count data w(j) and v(j) are unknown, since 
absolute abundance information is not available. However, by dividing observed sequencing 
counts by the total library size, we get compositional data vectors,  
and , with associated relative abundance matrices  and 
, where  is the p-dimensional unit simplex. It is well 
known that components of a composition are not independent due to the unit sum constraint, and 
covariance matrices of compositional data exhibit negative bias due to closure. It follows that, 
compositional data can be completely determined by the absolute abundance data it was 
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generated from (termed a basis), i.e. dividing by the total library size  
. 
As noted by John Aitchison, the equivalence 
, (3.1) 
implies that statistical inferences drawn from the analysis of the log-ratios of compositions 
( ) are equivalent to those drawn from analysis of log-ratios of the basis components 
( ). This equivalence establishes the precedence of log-ratio transformations to study 
compositional data. The centered log-ratio (CLR) transformation,  
CLR(x) = , where , 
is particularly useful, as it is symmetric and isometric (equal in dimension) with respect to the 
original composition (x). The CLR maps compositional data from the d-dimensional unit simplex 
to a (d − 1)-hyperplane of d-dimensional Euclidean space. This mapping also applies to the 
population covariance matrix such that ΓX = Cov[CLR(X)]. The matrix ΓX is related to the 
population covariance of the log-transformed absolute abundances, ΩW = Cov[logW] by 
ΓX = GdΩWGd,  (3.2) 
where , is the standard centering matrix, where Id is the d × d identity matrix 
and 1 is a d-length vector of ones. Therefore, for high dimensional data, , 
Gd ≈ Id,  (3.3) 
 83 
and ΓX ≈ ΩW is a reasonable approximation. The sparsity conditions necessary to approximately 
identify the covariance structure ΩW  from ΓX, have recently been shown, and have recovery 
guarantees based on sparsity, dimensionality, and sample size (120). 
The equivalence in Equation 3.1 and the ability to identify the population covariance 
structure from log-transformed absolute abundance are the foundation of SPIEC-EASI, which 
seeks to estimate a sparse inverse covariance (precision) matrix using the population covariance 
matrix as input. SPIEC-EASI uses the glasso method to solve the optimization problem, 
  (3.4) 
where ΓˆX is the empirical covariance estimate of CLR(X) and PD is the set of all positive definite 
matrices. Solving Equation 3.4 ensures that the penalized estimator is full rank, with a sparsity 
pattern that depends on the value of λ, since the L1 norm, , penalizes the absolute values of 
the row sums of the symmetric inverse covariance matrix ( ). In the Gaussian case, the 
network, or graphical model, is specified from the non-zero entries of . 
It is apparent that because they are amplifying and sequencing different marker genes that 
do not compete for reads, cross-domain studies generate technically independent compositions. 
Therefore, a naive application of Equation 3.4 directly to the combined dataset , an 
matrix generated from a simple concatenation of two compositional datasets, would 
be inappropriate. 
To illustrate this, consider that the log-ratio 
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 (3.5) 
does not satisfy the scale-invariance property of Equation 3.1. Similarly, Approximation 3.3 
does not hold between cross-compositional pairs. 
We instead consider the data matrix , generated by concatenating 
independently transformed compositions. The matrix ΓZ = Cov[Z] now has the following relation 
to the basis covariances: 
, (3.6) 
where ΩWV = Cov[logW,logV ], the cross-covariance matrix between the two log-transformed 
basis datasets, and ΩVW = (ΩWV)T. In other words, the (d + p) × (d + p) combined covariance 
structure ΓZ is decomposable into blocks where Approximation 3.3 holds. If , then the 
approximation 
 (3.7) 
allows us to use ΓˆZ as the input to Equation 3.4 to get a penalized estimator Ωˆ−Z1. This estimate 
is interpretable as an intra- and cross-domain interaction network, using the standard SPIEC-
EASI pipeline. Going beyond two domains follows directly from this and is left to the reader. 
3.4.2 Datasets 
In this study, we analyzed two previously published microbiota datasets that included both 
bacterial and fungal sequences. The first was from BALs collected as part of the Lung HIV 
Microbiome Project, as published in (4) and (40). It contained 35 samples that were subjected to 
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16S rRNA gene and ITS sequencing. The BAL samples originated from the right middle lobe or 
the left upper lobe of the lungs from 25 individuals, of whom 14 were HIV-infected and 11 were 
HIV-uninfected. Of the 35 samples, 17 came from individuals with normal spirometry and 18 
from individuals with COPD (diffusing capacity of the lungs from carbon monoxide (DLCO) < 
80% or forced expiratory volume in 1 second (FEV1) < 70%). The demographics of the cohort 
analyzed here can be found in Table 3.1. No significant differences were found between HIV-
infected and HIV-uninfected or between individuals with COPD and those with normal lung 
function. 
The second dataset was from a skin microbiome study at the National Human Genome 
Research Institute, as published in (114) and (115). It includes 382 samples from 14 body sites 
on 10 healthy adults. Ten body sites were repeated on the left and right sides, and some of the 
healthy volunteers underwent repeat sampling 1-3 months after their initial visits. 
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Table 3.1: Demographics of the lung microbiome cohort. Values are presented as mean (SD) except for those 
that are the percentage of the subset denoted with (%). P-values are from Welch t-tests for continuous 
variables and from Fisher’s exact tests for percentages. 
 Cohort HIV+ HIV- p-value COPD+ COPD- p-value 
N 25 14 11 - 13 12 - 
Age (yrs) 51.5 
(7.7) 
51.2 
(8.3) 
51.9 
(7.4) 
0.8472 49.4 
(8.1) 
53.6 
(7.1) 
0.2032 
Male (%) 88.0 92.9 81.8 0.5648 92.3 83.3 0.5930 
White (%) 56.0 50.0 63.6 0.6887 53.8 58.3 1.0000 
Current 
Smokers 
(%) 
20.0 28.6 9.1 0.4913* 30.8 8.3 0.4671* 
Former 
Smokers 
(%) 
12.0 14.3 9.1 7.7 16.7 
BMI  25.9 
(5.3) 
24.2 
(4.2) 
28.1 
(5.9) 
0.0792 24.4 
(5.4) 
27.6 
(4.8) 
0.1426 
Viral Load - 1476.9 
(2849.5) 
- - 2053.5 
(3230.5; 
N=10) 
35.5 
(18.2; 
N=4) 
0.0746 
CD4 count - 645.7 
(305.3) 
- - 620.2 
(326.2; 
N=10) 
701.8 
(278.8; 
N=4) 
0.6195 
*Smoking status p-value calculated using an ANOVA test. 
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Table 3.1 Continued 
FEV1/FVC 79.0 
(11.5) 
80.1 
(8.8) 
77.7 
(14.6) 
0.6435 75.8 
(15.0) 
82.5 
(4.1) 
0.1463 
DLCO  77.2 
(15.3) 
73.3 
(16.0) 
82.1 
(13.5) 
0.1520 66.8 
(13.9) 
88.4 
(6.0) 
<0.0001 
 
 
 
3.4.3 Sample and sequence processing 
Sample processing procedures for the lung microbiome have been previously described (4, 40). 
In brief, all samples had DNA extracted using standard techniques of the PowerSoil® DNA 
Isolation Kit from MO BIO (Carlsbad, CA). For bacterial DNA sequencing, the hyper-variable 
regions 1 through 3 (V1-V3) were amplified and sequenced using the Roche 454 GS-FLX 
Titanium platform. For fungal DNA sequencing, the ITS1 was amplified and sequenced on the 
Ion PGMTM Sequencer using the 400 bp protocol (60). 
The sample processing procedures for the skin microbiome were previously described 
(114, 115). In brief, samples were lysed using the MasterPureTM Yeast DNA Purification Kit, cell 
walls were mechanically disrupted using a Tissuelyser (Qiagen, Valencia, CA), and DNA was 
extracted using the Invitrogen PureLink Genomic DNA Kit (Invitrogen, Carlsbad, CA). For 
bacteria DNA sequencing, the V1-V3 regions were amplified and for fungal DNA sequencing 
the ITS1 region was amplified. Both bacterial and fungal DNA was sequenced on the Roche 454 
GS20/FLX platform with Titanium chemistry (Roche, Branford, CT). We analyzed the resulting 
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sequences in a manner consistent with the lung microbiome, which was different from that used 
in the original publications. 
All sequences from both the lung and skin microbiomes were processed using the QIIME 
pipeline version 1.7 (84) with default settings for de novo Operational Taxonomic Unit (OTU) 
picking at 97% similarity for bacteria and 99% similarity for fungi. Additional processing for the 
ITS sequences was performed using FHiTINGS (85). Samples with fewer than 1,000 16S 
bacterial reads (N=12 for the lung microbiome; N=12 for the skin microbiome) and samples with 
fewer than 50 ITS fungal reads (N=11 for the lung mycobiome; N=3 for the skin microbiome) 
were considered to have failed and were removed from further analysis. Bacterial taxonomic 
assignments were made using the Green Genes 12.10 reference database (62) and fungal 
taxonomic assignments were made using the FHiTINGS version of the Index Fungorum 
(http://www.indexfungorum.org/) reference database (85). 
We removed OTUs present in fewer than 1/3 of the samples (20 lung samples or 120 skin 
samples) as well as any OTUs represented by single reads in every sample. The number of 
samples, bacterial and fungal OTUs of each resulting network dataset are presented in Table 3.2. 
A pseudo count of 1 read was added to every OTU in every sample to eliminate zeros in samples 
where OTUs were absent. All OTU counts were normalized using total sum scaling (also known 
as relative abundance) followed by centered log ratio scaling (121), as described above.  
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Table 3.2 Dataset sizes for each network constructed. Amplification of target genes and sequencing were not 
successful for all samples resulting in variable node counts in the combined networks. 
Network Samples Bacteria OTU Nodes Fungi OTU Nodes 
Lung bacteria only 77 302 -- 
Lung fungi only 48 -- 96 
Lung combined 35 302 68 
Skin bacteria only 360 153 -- 
Skin fungi only 375 -- 94 
Skin combined 353 144 85 
 
 
 
3.4.4 Constructing Networks 
All networks were constructed using the SpiecEasi package version 0.1 in R 
(https://github.com/zdk123/SpiecEasi). We used the glasso estimation method to build the initial 
networks and selected the optimal sparsity parameter based on the stability approach to 
regularization selection (STARS) criteria (122). The STARS variability threshold was set to 0.1 
for all networks. 
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3.4.5 Evaluating and Comparing Networks 
Networks were evaluated using functions of the R package igraph version 1.0.1 (123). We 
evaluated node degree (i.e. the count of edges a node has) as a measure of sparsity. A complete 
network would have an average node degree equal to the number of nodes minus 1; a lower 
degree indicates a more sparse network. We measured assortativity by phyla with the nominal 
assortativity coefficient, which is designed to measure clustering by categorical variables. Higher 
coefficients indicate more clustering within categories. To evaluate connectedness of the 
networks, we used normalized node betweenness centrality for undirected graphs. Normalized 
node betweenness centrality measures the proportion of the shortest paths in the network that 
pass through the node. A lower average betweenness centrality number indicates a more 
connected network, either because of more shortest-paths, or because fewer of the shortest paths 
travel through each node. These metrics, as well as distance between nodes, were used to 
compare the networks using Welch’s unequal variances t-tests (124).  
3.4.6 Microbial Co-cultures 
All organisms were purchased from ATCC and grown under their recommended conditions 
(Table 3.3) to establish stocks. From these stocks, uniform condition stocks were inoculated in 
brain heart infusion (BHI) broth and incubated at 37°C under aerobic conditions. These same 
uniform conditions were used to grow mono, dual, and tri organism co-cultures, each started 
with the same number of cells of each organism (10 million bacterial cells or 1 million fungal 
spores). Growth was measured by cellular density every 24 hours for 5 days, and curves were fit 
by connecting the average of 3 biological replicates. To ensure that cells were maintaining 
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viability, aliquots were plated on BHI agar at each time point and colony forming units (CFUs) 
were counted after a 24-hour incubation period. A complete standard operating procedure for 
microbial co-cultures is located in Appendix B. 
 
 
 
 
Table 3.3: Organisms and their recommended growing conditions. Each of the three microbes used in co-
culture validation experiments was purchased from ATCC, rehydrated, and grown under their 
recommended conditions before co-culturing began. The ATCC catalogue numbers and recommended 
growing conditions are presented here. Because P. acnes is an anaerobe, it was first grown in a homemade 
anaerobic jar inside the incubator. 
Organism ATCC 
catalogue 
number 
Recommended 
Temperature 
Recommended Media 
Emericella nidulans 96921 24°C Malt extract agar 
Propionibacterium 
acnes 
6919 37°C Tryptic soy agar with 5% sheep 
blood 
Rothia dentocariosa 17931 37°C Brain-heart infusion agar 
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3.4.7 Accession Numbers 
The sequencing data from the lung microbiome used in this study are available in the Sequence 
Read Archive (SRA) under the following accession numbers: SRP065274 for 16S and 
SRP040237 for ITS. The sequencing data from the skin microbiome used here are available in 
GenBank under accession numbers GQ000001 to GQ116391 for 16S and KC669797 to 
KC675175 for ITS. 
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4.0  MULTI-OMICS INVESTIGATION OF THE LUNG MICROBIOME6 
 
4.1 BACKGROUND 
The composition of the lung microbial community differs under conditions of chronic 
obstructive pulmonary disease (COPD) (3, 23, 24, 125), cystic fibrosis (20), lung transplant (25), 
and other diseased states. Yet the functional role of the lung microbiome in health and disease 
has not yet been clearly defined. It has been hypothesized that the inflammation seen in COPD is 
a result of the host’s immune response to the bacteria present in the lungs (22). This hypothesis is 
supported in part by the increased abundance of opportunistic pathogens during COPD (126, 
127) but is hindered by inconsistent findings of shifts in the sputum microbiome community 
during COPD exacerbations. One study found increased abundance of COPD-related pathogens, 
including Haemophilus influenzae (127), while another study found no significant shifts in the 
community composition (128). These discrepancies highlight the limitations of taxonomy-based 
studies and the need to perform functional assessments of the microbial community.  
                                                 
6 Paper in preparation. 
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One population where functional differences in the lung microbiome community may be 
especially relevant is the HIV-infected population. HIV is an independent risk factor for COPD, 
regardless of smoking history (129–131). Opportunistic pathogens associated with COPD may 
have more opportunities to infect patients with HIV given the subtle immune deficits observed, 
even in treated HIV infection. These subtle immune deficits have not been shown to have an 
impact on the lung microbiota (27) but this study did not include patients with impaired lung 
function.  
To investigate the metabolism of the lung microbiome, we examined datasets from 16S 
rRNA target gene sequencing, metatranscriptome analysis, and metabolomic mass-to-charge 
ratio (m/z) features found in the bronchoalveolar lavage (BAL) of subjects with COPD and HIV. 
First, we looked at each dataset alone for overt differences. As observed in other studies, we 
found minimal differences in 16S rRNA gene-based community composition for both COPD and 
HIV (3, 23, 27). We also found minimal differences in gene family expression levels and global 
m/z feature abundance for both COPD and HIV. We looked at correlations between dataset pairs, 
and compared the information that could be learned from each data set independently, including 
taxonomic compositions and metabolic functions defined by Kyoto Encyclopedia of Genes and 
Genomes (KEGG) ontology (KO) terms (132, 133). While we found many differences in the 
taxonomic assignments and metabolic functions, we saw overlap in metabolic functions 
associated with HIV infection and COPD. Finally, we integrated all three datasets using a sparse 
multi-block partial least squares (sMBPLS) regression (134) to identify blocks of associated 
operational taxonomic units (OTUs) from the 16S rRNA gene sequences, gene families from the 
metatranscriptome sequences, and m/z features from the metabolomics. We examined each block 
for pathway enrichment among the m/z features and corresponding gene families in the same 
 95 
pathways. Analysis of the OTUs associated with the enriched metabolic pathways indicated that 
important pathways were encoded and expressed by bacteria not considered high producers of 
the pathway products, or that certain pathways were completed across multiple bacterial species. 
4.2 RESULTS 
4.2.1 Single datasets 
For each of our 25 samples, we have three “-omics” datasets: the 16S rRNA gene sequences, 
which were clustered into 1,142 OTUs and used for taxonomic community composition; the 
metatranscriptomic sequences, which were mapped to 145,574 UniRef50 gene families; and the 
metabolomic m/z features, of which there were 5,868. We tested each of the three datasets for 
differences in abundance or expression based on COPD status and HIV infection using Wilcoxon 
tests.  
Among the OTUs, we found that the community composition could not distinguish 
between COPD and normal lung function, nor between uninfected and HIV infected patients 
(Figure 4.1A). These comparisons had adonis PERMANOVA p-values of 0.051 and 0.053, 
respectively. We tested each OTU for differential abundance and found 87 to be nominally 
differentially abundant by COPD status, and 57 to be nominally differentially abundant by HIV 
infection. No OTUs were significantly differentially abundant following correction for multiple 
hypotheses testing. Of the OTUs that were nominally differentially abundant by COPD, 10 were 
over-abundant and 48 were under-abundant in COPD patients, as measured by median relative 
abundance (Table 4.1). When comparing HIV infection, 56 OTUs were under-abundant in HIV 
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infection, based on median relative abundance (Table 4.2). The single OTU that was over-
abundant in HIV infection is classified as a member of the S24-7 family, an uncultured member 
of the Bacterodales order predicted to thrive in low-oxygen environments including mammalian 
guts (135). 
We were able to detect a significant difference in community composition between 
COPD and normal lung function (adonis p-value 0.030) when we removed samples dominated 
by environmental bacteria. Specifically, the six samples that contained more than 50% relative 
abundance of the family Microbacteriaceae were removed (samples 8, 9, 10, 14, 20, and 22 in 
Figure 4.3). This bacterial family has previously been found to be a contaminant in DNA 
extraction kits (58) and the over-abundance of this family in these samples lead to their 
exclusion. Of these six samples, five originated from participants with COPD and one from a 
participant with normal lung function. All six samples originated from participants that were 
HIV-infected but when they were removed there remained no significant difference in 
community composition between HIV-infected and uninfected samples (adonis p-value 0.027). 
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Figure 4.1 Ordination plots for COPD (left column) and HIV (right column) comparisons. (A) Principle 
Coordinates Analysis (PCoA) of OTUs based on Bray-Curtis distance. (B) PCoA of gene families based on 
Bray-Curtis distance. (C) Principle Component Analysis (PCA) of m/z features. 
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Table 4.1: List of OTUs differentially abundant in COPD by their lowest taxonomic assignments. OTUs with 
equal median relative abundance are not listed (N=29). 
Taxonomy Number of OTUs Over/Under Abundant in 
COPD 
Acinetobacter 1 Under 
Bradyrhizobium 1 Under 
Campylobacter 1 Under 
Catonella 1 Under 
Gemella 1 Under 
Granulicatealla 1 Under 
Fusobacterium 1 Under 
Haemophilus 1 Under 
Lactobacillus 1 Under 
Leptotrichia 1 Under 
Micrococcus 1 Over 
Mycoplasma 1 Under 
Neisseria 1 Under 
Oribacterium 1 Under 
Prevotella 2 Over 
Prevotella 5 Under 
Streptococcus 4 Under 
Treponema 1 Under 
 
Table 4.1 Continued 
 99 
Trichoccus 1 Under 
Comamonadaceae (family) 1 Under 
Lachnospiraceae (family) 1 Under 
Mogibacteriaceae (family) 1 Under 
Neisseriaceae (family) 1 Over 
S24-7 (family) 1 Under 
Weeksellaceae (family) 1 Under 
Bacillales (order) 1 Under 
Clostridiales (order) 1 Under 
Streptophyta (order) 1 Over 
SR1 (phylum) 1 Over 
Unclassified 4 Over 
Unclassified 17 Under 
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Table 4.2: List of OTUs differentially abundant in HIV by their lowest taxonomic assignments. 
Taxonomy Number of OTUs Over/Under Abundant in 
HIV 
Actinomyces 1 Over 
Bradyrhizobium 1 Over 
Campylobacter 1 Over 
Corynebacterium 1 Over 
Enterococcus 1 Over 
Fusobacterium 1 Over 
Gemella 1 Over 
Haemophilus 2 Over 
Leptotrichia 1 Over 
Micrococcus 1 Over 
Moryella 1 Over 
Neisseria 1 Over 
Oribacterium 1 Over 
Prevotella 4 Over 
Rothia 1 Over 
Streptococcus 7 Over 
Trichococcus 1 Over 
Aeromonadaceae (family) 1 Over 
Comamondaceae (family) 1 Over 
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Table 4.2 Continued 
Enterobacteriaceae (family) 1 Over 
Lachnospiraceae (family) 1 Over 
Mogibacteriaceae (family) 1 Over 
Neisseriaceae (family) 1 Over 
S24-7 (family) 1 Under 
Bacillales (order) 1 Over 
SR1 (phylum) 1 Over 
Unassigned 21 Over 
 
 
 
Similar to the OTU community abundance, from the metatranscriptome data we saw no 
difference in the composition of the gene families between COPD and normal lung function, nor 
between uninfected and HIV infected subjects (Figure 4.1B). These comparisons had adonis 
PERMANOVA p-values of 0.084 and 0.583, respectively. Each gene family was tested for 
differential expression in COPD and HIV infection. In COPD, 477 gene families were nominally 
significantly over-expressed and 9,230 gene families were nominally significantly under-
expressed, based on median reads per kilobase (RPKs). Additionally, 9,598 gene families were 
considered nominally significantly different, but had the same median RPKs. In HIV infection, 
499 gene families were nominally significantly over-expressed, 894 were nominally significantly 
under-expressed, and 312 gene families were considered significantly differentially expressed 
but had the same median RPKs. While these numbers may seem large in absolutes, the majority 
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of gene families being expressed are not significantly differentially expressed; 96.8% of gene 
families are equally expressed in COPD and normal lung function, and 99.8% are equally 
expressed in HIV-infected and uninfected subjects. 
Finally, among the composition of all m/z features, we saw no significant difference in 
either COPD or HIV infection (Figure 4.1C). The PERMANOVA p-values for these 
comparisons were 0.448 and 0.051, respectively. In COPD, 88 m/z features were nominally 
significantly over-abundant and 80 m/z features were nominally significantly under-abundant, 
based on median values. None of these m/z features could be mapped to unique metabolites. 
Only two of the 5,868 m/z features could be mapped to unique metabolites: m/z 268.1907 
mapped to 2-(3-AMINO-4-CYCLOHEXYL-2-HYDROXY-BUTYL)-PENT-4-YNOIC ACID, 
part of an archetypical dehalogenase, and m/z 999.3511 mapped to Sialyllacto-N-tetraose b, an 
oligosaccharide found in human breast milk. When we ran the m/z features that were nominally 
significantly different in COPD through mummichog, a pipeline that identifies pathway 
enrichment from m/z features bypassing assignments to unique metabolites (136), no pathways 
were found to have an overlap of more than two predicted metabolites. In HIV, 90 m/z features 
were nominally significantly over-abundant and 58 were nominally significantly under-abundant, 
based on median values. Again, none of these m/z features could be mapped to unique 
metabolites. When we ran the nominally significant m/z features through mummichog, the top 
pathways included valine, leucine, and isoleucine degradation (overlap of 5 out of 34 predicted 
metabolites, p-value = 0.0014), butanoate metabolism (overlap of 4 out of 23 predicted 
metabolites, p-value = 0.0015), keratin sulfate degradation (overlap of 2 out of 3 predicted 
metabolites, p-value = 0.0018), and tryptophan metabolism (overlap of 5 out of 39 predicted 
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metabolites, p-value = 0.0018). Although not as extreme as in COPD, the overlap of predicted 
metabolites is low in all pathways enriched in HIV-infection.   
4.2.2 Two datasets 
4.2.2.1 Correlations 
For every pair of datasets, we calculated the Spearman (non-linear) correlations between all 
features at relevant abundances (greater than 0.1% average abundance). Overall, the correlations 
were skewed slightly positive (53.5%) but ranged from ρ = -0.77, between an OTU classified as 
Prevotella and the gene family A0A009RUM8: putative outer membrane protein (fragment), to ρ 
= 0.81 between an OTU classified as Actinobacillus and an m/z feature of 132.00, which could 
not be mapped to any unique metabolite.  
Between OTUs and gene families, out of 3,440 correlations, 1,839 (53.5%) were positive 
and 1,601 (46.5%) were negative (Figure 4.2 upper left). Of these, 151 of the positive 
correlations and 295 of the negative correlations were statistically significant (ρ > 0.4 or < - 0.4). 
Between OTUs and m/z features, out of 8,514 correlations, 4,359 (51.2%) were positive with 463 
being significantly positive, and 4,155 (48.8%) were negative with 280 being significantly 
negative (Figure 4.2 upper right). This pair of datasets had some of the strongest correlations, 
many of which were with an OTU classified as Actinobacillus, a member of the healthy 
respiratory tract microbiome (137, 138). This OTU had an average relative abundance of 0.13% 
(sd 0.31) and was present in 12 of the 25 samples, all of which originated from patients with HIV 
infection. Between gene families and m/z features, out of 3,960 correlations, 2,309 (58.3%) are 
positive and 1,646 (41.6%) were negative (Figure 4.2 lower right). Of these, 182 were 
significantly positive and 67 were significantly negative. 
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Figure 4.2 Correlations between pairs of datasets. Each dot represents a pair of features, sized according to 
the magnitude of the correlation, and colored by the Spearman correlation between them (red is negative 
correlation and blue is positive correlation); darker dots indicate significant correlations. 
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4.2.2.2 Taxonomic Composition Comparison 
We calculated the taxonomic compositions of the BAL samples based on the 16S rRNA gene 
amplicons and metatranscriptome reads; metatranscriptome-based taxonomic assignments could 
not be completed for three of the samples thus a comparison across data sets was done for 22/25 
samples available. For the metatranscriptome data, taxonomic assignments are based on 
matching k-mers in the sequencing reads to sequenced whole genomes and were collapsed to the 
genus level since 16S rRNA gene data are generally not sensitive enough to allow taxonomic 
assignments down to the species. Genera that were found in only 1 or 2 samples were removed, 
leading to a total of 153 genera identified in the 16S rRNA gene data and 553 in the 
metatranscriptome data. Relative abundance plots show how different the taxonomic profiling 
appears in the 16S gene data and the metatranscriptome (Figure 4.3). In addition to non-bacterial 
genera, including the eukaryotic genus Toxoplasma and viral ‘genus’ Enterovirus, the 
metatranscriptome measured bacterial genera that were not detected by 16S rRNA gene 
sequencing. This occurred when either the genera were not in the reference database, (for 
example, Tropheryma), or because the 16S rRNA gene sequences are not appropriately targeted 
by the primers. Of the 71 genera that could be detected by both platforms, the Pearson (linear) 
correlation of abundance ranged from -0.42 to 0.93 (average 0.09; sd 0.28). Only 4 of the 71 
correlations were significant, after adjusting for multiple hypothesis testing: Prevotella (r = 
0.67), Megasphaera (r = 0.69), Filifactor (r = 0.93), and Nesterenkonia (r = 0.93). All of these 
genera except Nesterenkonia are common members of the human oral microbiome (139). These 
correlated genera ranged in average relative abundance from 10.0% (sd 9.7) for the 16S rRNA 
gene assignments and 6.8% (sd 14.1) for the metatranscriptome read assignments for Prevotella, 
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down to 0.02% (sd 0.07) for the 16S rRNA gene assignments and 0.007% (sd 0.03) for the 
metatranscriptome read assignments for Nesterenkonia. 
When collapsed to the taxonomic level of class, the 16S rRNA gene assignments and 
metatranscriptome read assignments look more similar (Figure 4.4). Beyond the inclusion of 
Picornaviridea viruses and Coccidia protozoa, the metatranscriptome read assignments include 
the class Negatativicutes. These members of Firmicutes phylum include the genera Veillonella, 
which is sometimes placed in the neighboring Clostridia class (62, 63). Other differences may 
reflect dead or inactive bacteria whose DNA is still being detected in the 16S rRNA gene 
assignments.  
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Figure 4.3 Relative abundance plots for assigned taxonomies at the genus level. Highlighted genera are present at greater than 10% abundance in at 
least one sample from one platform. Taxonomic assignments from (A) 16S rRNA gene sequences and (B) metatranscriptomic sequences. 
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Figure 4.4 Relative abundance plots for assigned taxonomy at the class level. Highlighted classes represent the top 10 classes based on average relative 
abundance in either (A) 16S rRNA gene sequences or (B) metatranscriptome sequences. 
 109 
4.2.2.3 KEGG Ontology Comparison 
To examine the functional profile of the BAL community, we used PICRUSt (140) to predict the 
metagenome and metabolic potential from the 16S rRNA gene data, and HUMAnN2 (141) to 
calculate the expression of transcribed metabolic functions from the metatranscriptomic reads. 
The predicted metagenome contained 6,909 KO terms based on 749,878 (53%) of the 16S rRNA 
gene sequences across all samples. The remaining 47% of the sequences were removed for this 
analysis because they were not within 97% similarity to the reference database. The average 
nearest sequenced taxon index (NSTI) distance was 0.03 (sd 0.02). This indicates that the 
predicted metagenome is based on sequences that are, on average, from the same (97% similar) 
OTUs as our samples. The expressed metabolic functions included 3,490 KO terms based on 6.6 
million metatranscriptome reads, across all samples, normalized on metagenomic reads from the 
same samples. This normalization resulted in the inclusion at low levels of KO terms present but 
not expressed and reduced the expression levels of highly abundant KO terms. 
We then compared the abundance and expression levels of each KO term using Pearson 
correlations. We were able to match 3,490 KO terms between the PICRUSt predicted 
metagenome and the metatranscriptome. Correlations between these two datasets ranged from -
0.3 to 1.0, with 325 (9.3%) KO terms being nominally significantly correlated (Figure 4.4), 
where nominal significance is defined as a Pearson correlation test with a p-value < 0.05, 
equivalent to a Pearson correlation coefficient of 0.4. These strong positive correlations indicate 
functions that are being expressed proportionally to their predicted abundance and thus the 
metatranscriptome and predicted metagenome data reveal the same trends. While no negative 
correlations reach significance, 2,157 (62%) of the KO terms were negatively correlated between 
the predicted metagenome and the metatranscriptome. Even though they are not significant, these 
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negative correlations indicate functions that are either highly expressed despite low predicted 
abundance or are slightly expressed despite high predicted abundance.  
The KO terms identified were used to look for differential abundance and differential 
expression between HIV infected individuals (N=6) and HIV uninfected individuals (N=19). We 
compared the list of KO terms identified as differentially abundant or expressed between the 
predicted metagenome and the metatranscriptome data, as well as the direction (over 
abundant/expressed or under abundant/expressed) of all KO terms. Even when KO terms were 
identified as differentially abundant and differentially expressed for both, the direction was not 
always the same. The predicted metagenome and metatranscriptome both called four KO terms 
differentially abundant and differentially expressed (Table 4.3). On these 4 terms, there was 
agreement on the direction for 3 of them (75%). Overall, there was 54% agreement on direction 
(Figure 4.5A). 
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Figure 4.5 Comparison of KO terms between the predicted metabolic functions from the 16S rRNA gene 
sequences and the metatranscriptomic gene family assignments.  Shows the linear correlation coefficient (on 
Y-axis) between the two platforms for each KO term that was identified in both datasets. The solid line at a 
Pearson Correlation of 1 represents perfect correlation, achieved only by K01909: long-chain-fatty-acid—
[acyl-carrier-protein] ligase. The dashed line at a Pearson Correlation of 0.4 represents nominally significant 
correlations, of which there are 325 (9.3%). 
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Table 4.3: KEGG Ontology terms determined to be differentially abundant/expressed in HIV by both the 
predicted metagenome and the metatranscriptome. The direction of differential abundance is presented in 
column 3, “Over abundant” indicates that the KEGG term is more abundant in HIV-infected samples than 
uninfected samples and “Under abundant” indicates that it is more abundant in HIV-uninfected samples 
than infected samples. The direction of differential expression is presented in column 4, “Over expressed” 
indicates that the term is transcribed or expressed more in HIV-infected samples than uninfected samples. 
KEGG 
ID 
Definition Predicted Metagenome 
Differential Abundance 
in HIV Direction 
Metatranscriptome 
Differential 
Expression in HIV 
Direction 
K00067 dTDP-4-
dehydrorhamnose 
reductase 
Over abundant Over expressed 
K00163 pyruvate dehydrogenase 
E1 component 
Over abundant Over expressed 
K00845 glucokinase Over abundant Over expressed 
K14205 phosphatidylglycerol 
lysyltransferase 
Under abundant Over expressed 
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Similarly, we looked for differential abundance and differential expression between 
individuals with normal lung function (N=8) and those with COPD (N=17), where COPD was 
defined as having diffusing capacity of the lungs from carbon monoxide (DLCO) < 80% or 
forced expiratory volume in 1 second (FEV1) < 70%. As in the HIV comparison, the direction of 
the differential abundance and differential expression was not the same between the predicted 
metagenome and the metatranscriptome, even if both platforms identified the KO term as being 
differentially abundant and differentially expressed. The predicted metagenome and the 
metatranscriptome both called 11 KO terms differentially abundant and differentially expressed, 
presented in Table 4.4. Of these terms, the two platforms agree on the direction of 7 of them 
(64%). Over all KO terms, they had 51% agreement on direction (Figure 4.5B). 
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Figure 4.6 Significance of differential abundance/expression of KO terms. Plotted are the p-values resulting 
from Wilcoxon tests between (A) HIV-infected and uninfected patients and(B) between patients with COPD 
and with normal lung function. In these plots, green dots represent KO terms that are over-abundant and 
over-expressed in HIV and COPD, red dots represent KO terms that are under-abundant and under-
expressed in HIV and COPD, and grey dots represent KO terms for which the direction of abundance and 
expression do not match. Dashed lines are included at p=0.05 to indicate nominal statistical significance. No 
attempt was made to correct for multiple hypotheses testing.  
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Table 4.4: KEGG Ontology terms determined to be differentially abundant/expressed in COPD by both the 
predicted metagenome and the metatranscriptome. The direction of differential abundance is presented in 
column 3, “Over abundant” indicates that the KEGG term is more abundant in COPD positive samples than 
samples with normal lung function and “Under abundant” indicates that it is more abundant in samples with 
normal lung function than COPD positive samples. The direction of differential expression is presented in 
column 4, “Over expressed” indicates that the term is transcribed or expressed more in COPD positive 
samples than samples with normal lung function and “Under expression” indicates that the term is 
transcribed or expressed more in samples with normal lung function than those with COPD. 
KEGG 
ID 
Definition Predicted Metagenome 
Differential Abundance 
in COPD Direction 
Metatranscriptome 
Differential 
Expression in COPD 
Direction 
K00174 2-oxoglutarate/2-
oxoacid ferredoxin 
oxidoreductase subunit 
alpha 
Over abundant Over expressed 
K00610 aspartate 
carbamoyltransferase 
regulatory subunit 
Under abundant Under expressed 
K00851 Gluconokinase Over abundant Under expressed 
K01571 oxaloacetate 
decarboxylase, alpha 
subunit 
Over abundant Under expressed 
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Table 4.4 Continued 
K01968 3-methylcrotonyl-CoA 
carboxylase alpha 
subunit 
Over abundant Under expressed 
K03146 thiamine thiazole 
synthase 
Under abundant Under expressed 
K03955 NADH dehydrogenase 
(ubiquinone) 1 
alpha/beta subcomplex 1 
Under abundant Under expressed 
K05565 multicomponent 
Na+:H+ antiporter 
subunit A 
Under abundant Under expressed 
K09002 CRISPR-associated 
protein Csm3 
Under abundant Under expressed 
K10793 D-proline reductase 
(dithiol) PrdA 
Under abundant Under expressed 
K11903 type VI secretion system 
secreted protein Hcp 
Over abundant Under expressed 
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4.2.3 Three Datasets 
4.2.3.1 Block Identification 
To generate hypotheses about what OTUs were transcribing which gene families to produce 
specific metabolites, we integrated the datasets from the 16S rRNA target gene sequences, the 
metatranscriptome, and the metabolome. We used sparse multi-block partial least squares 
(sMBPLS) regression (134) to identify blocks of OTUs that are associated with gene families 
and are producing specific m/z features. The regression produced 93 blocks that contained 127 to 
575 OTUs, 29,320 to 90,570 gene families, and 1,438 to 3,335 m/z features. Block 15 is shown 
as an example in Figure 4.6. This block contains 437 OTUs, 36,778 gene families, and 1,438 m/z 
features. Within each block, we searched the metabolites for pathway enrichment with 
mummichog. The most commonly enriched pathway, i.e. the top pathway in 70 (75.3%) of the 
blocks, was aspartate and asparagine metabolism (Table 4.5). Aspartate and asparagine 
metabolism was represented by 27 to 42 out of 55 metabolites, depending on the block (p-values 
between 0.0002 and 0.034).  
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Figure 4.7 Heatmaps of example block identified by sMBPLS, block 15. Each heatmap is broken into two 
sections separated by a cyan box which encircles the features included in the block. The section outside the 
box contains the features not included in the block. The components of block 15 include (A) 437 OTUs, (B) 
36,778 gene families, and (C) 1,438 m/z features.  
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Table 4.5: Top pathway identified for each block. Top pathway is defined as the pathway having the lowest 
adjusted p-value (see column 5) when comparing the m/z features in the cluster to all m/z features in the 
dataset with mummichog. Pathway names are from mummichog and a list of all possible pathways can be 
found at http://metafishnet.appspot.com/hbrowse.   
BlockID TopPathway Overlap RawP AdjP 
1 
Drug metabolism – cytochrome 
P450 27/30 0.02211 0.00156 
2 Linoleate metabolism 42722 0.03782 0.00311 
3 
Aspartate and asparagine 
metabolism 34/55 0.00263 0.00097 
4 de novo fatty acid biosynthesis 19/30 0.00267 0.00444 
5 
Aspartate and asparagine 
metabolism 27/55 0.09785 0.00481 
6 Linoleate metabolism 14/18 0.00265 0.00112 
7 Lysine metabolism 15/20 0.00422 0.00385 
8 Linoleate metabolism 15/18 0.00111 0.0036 
9 Linoleate metabolism 15/18 0.00007 0.00486 
10 Linoleate metabolism 15/18 0.00047 0.00496 
11 Omega-3 faty acid metabolism 13/16 0.00215 0.01344 
12 de novo fatty acid biosynthesis 20/30 0.00146 0.01937 
13 purine metabolism 21/35 0.04213 0.00738 
14 
Aspartate and asparagine 
metabolism 41/55 0 0.00492 
15 drug metabolism - other enzymes 42719 0.00061 0.0043 
16 Linoleate metabolism 14/18 0.00176 0.00074 
17 Linoleate metabolism 42722 0.01222 0.0039 
18 Linoleate metabolism 14/18 0.00065 0.00201 
19 de novo fatty acid biosynthesis 18/30 0.0412 0.00042 
20 purine metabolism 23/35 0.00985 0.00161 
21 de novo fatty acid biosynthesis 21/30 0.00083 0.00228 
22 Linoleate metabolism 17/18 0 0.00095 
23 
Di-unsaturated fatty acid beta-
oxidation 42592 0.01975 0.00166 
24 
Aspartate and asparagine 
metabolism 37/55 0.00061 0.00182 
25 Linoleate metabolism 16/18 0.00438 0.01027 
26 
Aspartate and asparagine 
metabolism 40/55 0 0.00078 
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Table 4.5 Continued 
27 
Aspartate and asparagine 
metabolism 41/55 0 0.00059 
28 
Aspartate and asparagine 
metabolism 40/55 0 0.00189 
29 
Aspartate and asparagine 
metabolism 40/55 0 0.0003 
30 
Aspartate and asparagine 
metabolism 41/55 0 0.00285 
31 
Aspartate and asparagine 
metabolism 41/55 0 0.00102 
32 
Aspartate and asparagine 
metabolism 40/55 0 0.00682 
33 
Aspartate and asparagine 
metabolism 40/55 0 0.00321 
34 
Aspartate and asparagine 
metabolism 41/55 0 0.00347 
35 
Aspartate and asparagine 
metabolism 38/55 0.00001 0.00507 
36 
Aspartate and asparagine 
metabolism 40/55 0 0.00096 
37 
Aspartate and asparagine 
metabolism 40/55 0 0.00197 
38 
Aspartate and asparagine 
metabolism 40/55 0 0.03319 
39 
Aspartate and asparagine 
metabolism 41/55 0 0.00185 
40 
Aspartate and asparagine 
metabolism 40/55 0 0.0068 
41 
Aspartate and asparagine 
metabolism 41/55 0 0.00225 
42 
Aspartate and asparagine 
metabolism 41/55 0 0.00324 
43 
Aspartate and asparagine 
metabolism 41/55 0 0.00232 
44 
Aspartate and asparagine 
metabolism 41/55 0 0.03446 
45 
Aspartate and asparagine 
metabolism 41/55 0 0.00368 
46 
Aspartate and asparagine 
metabolism 41/55 0 0.00117 
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Table 4.5 Continued 
47 
Aspartate and asparagine 
metabolism 40/55 0 0.00069 
48 
Aspartate and asparagine 
metabolism 40/55 0 0.00076 
49 
Aspartate and asparagine 
metabolism 41/55 0 0.00075 
50 
Aspartate and asparagine 
metabolism 41/55 0 0.00231 
51 
Aspartate and asparagine 
metabolism 41/55 0 0.00348 
52 
Aspartate and asparagine 
metabolism 41/55 0 0.01767 
53 
Aspartate and asparagine 
metabolism 41/55 0 0.00034 
54 
Aspartate and asparagine 
metabolism 41/55 0 0.00096 
55 
Aspartate and asparagine 
metabolism 41/55 0 0.00668 
56 
Aspartate and asparagine 
metabolism 41/55 0 0.00244 
57 
Aspartate and asparagine 
metabolism 41/55 0 0.00039 
58 
Aspartate and asparagine 
metabolism 41/55 0 0.00626 
59 
Aspartate and asparagine 
metabolism 41/55 0 0.00035 
60 
Aspartate and asparagine 
metabolism 41/55 0 0.00559 
61 
Aspartate and asparagine 
metabolism 41/55 0 0.01828 
62 
Aspartate and asparagine 
metabolism 41/55 0 0.00068 
63 
Aspartate and asparagine 
metabolism 41/55 0 0.0009 
64 
Aspartate and asparagine 
metabolism 41/55 0 0.00065 
65 
Aspartate and asparagine 
metabolism 41/55 0 0.00077 
66 
Aspartate and asparagine 
metabolism 41/55 0 0.00338 
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Table 4.5 Continued 
67 
Aspartate and asparagine 
metabolism 41/55 0 0.01674 
68 
Aspartate and asparagine 
metabolism 41/55 0 0.00344 
69 
Aspartate and asparagine 
metabolism 41/55 0 0.00121 
70 
Aspartate and asparagine 
metabolism 38/55 0.00003 0.008 
71 
Aspartate and asparagine 
metabolism 41/55 0 0.00187 
72 
Aspartate and asparagine 
metabolism 41/55 0 0.0006 
73 
Aspartate and asparagine 
metabolism 39/55 0.00002 0.0021 
74 
Aspartate and asparagine 
metabolism 39/55 0.00002 0.00257 
75 
Aspartate and asparagine 
metabolism 41/55 0 0.00137 
76 
Aspartate and asparagine 
metabolism 39/55 0.00002 0.00015 
77 
Aspartate and asparagine 
metabolism 41/55 0 0.00026 
78 
Aspartate and asparagine 
metabolism 41/55 0 0.00077 
79 
Aspartate and asparagine 
metabolism 41/55 0 0.00329 
80 
Aspartate and asparagine 
metabolism 41/55 0 0.00136 
81 
Aspartate and asparagine 
metabolism 41/55 0 0.00284 
82 
Aspartate and asparagine 
metabolism 41/55 0 0.00071 
83 
Aspartate and asparagine 
metabolism 41/55 0 0.0036 
84 
Aspartate and asparagine 
metabolism 41/55 0 0.00482 
85 
Aspartate and asparagine 
metabolism 41/55 0 0.00258 
86 
Aspartate and asparagine 
metabolism 41/55 0 0.00067 
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Table 4.5 Continued 
87 
Aspartate and asparagine 
metabolism 41/55 0 0.00067 
88 
Aspartate and asparagine 
metabolism 42/55 0 0.0011 
89 
Aspartate and asparagine 
metabolism 41/55 0 0.00193 
90 
Aspartate and asparagine 
metabolism 41/55 0 0.00337 
91 
Aspartate and asparagine 
metabolism 41/55 0 0.00315 
92 
Aspartate and asparagine 
metabolism 41/55 0 0.00025 
93 
Aspartate and asparagine 
metabolism 39/55 0.00002 0.00161 
 
 
 
To prove that these blocks had biological meaning, we looked at pathways completely 
covered by the m/z features (all metabolites present), verified that all the gene families were 
being transcribed within the block, and then looked to see if the OTUs belonged to bacteria that 
are known to use the pathway under investigation. Nitrogen metabolism is a small pathway that 
contains four metabolites and four gene families; while used by many bacteria, only a limited 
number of bacterial genera are known to be especially high nitrogen reducers. The pathway was 
completely covered by the metabolic features in 70 out of the 93 blocks. These blocks were more 
likely to contain members of all 4 gene families than blocks that did not completely cover the 
metabolic pathway (Fisher’s exact test p-value = 0.01). We defined high nitrogen reducers as 
members of the following genera: Rothia, Leptotrichia, Gemella, Treponema, Prevotella, 
Parvimonas, Staphylococcus, Streptococcus, Veillonella, Actinomyces, Neisseria, Heomophilus, 
and Granulicatella (142–147). Each of these genera were found in our data and all but 
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Heomophilus are common members of the human oral microbiome (139). Given this list, the 70 
blocks that cover the nitrogen metabolism pathway contained significantly more OTUs that are 
high nitrogen reducers than blocks that did not completely cover the pathway (Wilcoxon test p-
value = 0.021). We confirmed biological meaning of the blocks identified by sMBPLS with the 
blocks that cover the m/z features in the nitrogen metabolism pathway, showing enrichment of 
nitrogen reducing bacteria and of the gene families in the nitrogen metabolism pathways. 
Once the biological relevance of our identified blocks was established, we turned to a less 
ubiquitous metabolic pathway. A single block, block 4, completely covered the pathway for 
vitamin B2 (riboflavin) metabolism. This pathway contains only 3 metabolites. For gene 
families, block 4 is in the 94th percentile (ranked 87 out of 93, containing 51 gene families) for 
the number of gene families that contain the word “Riboflavin”. These gene families include 
riboflavin biosynthesis proteins RibA, ribAB, RibBA, PYRD, RibC, RibD, RibF, Riboflavin 
transporter RibU, Riboflavin kinase, and Riboflavin synthase. However, block 4 is one of only 6 
blocks that contains no members of either Corynebacterium or Micrococcus genera, which are 
known to be high riboflavin producers (148, 149). Instead, the block contained 1 OTU assigned 
to Lactobacillus and 13 OTUs assigned to Streptococcus, both of which are capable of 
synthesizing riboflavin in vitro (150) but not at high levels.   
 
4.3 DISCUSSION 
We set out to describe the metabolism of the lung microbiome in health, and examine shifts 
during COPD and HIV-infection. In the individual datasets, we found no overt shifts in OTU 
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community composition, gene family expression levels, or m/z feature abundance. This result 
was different from, but not contradictory to our previous findings where we saw no shifts in the 
OTU community composition in HIV-infection but identified a signature subset of 12 m/z 
features that could distinguish between HIV-infected and uninfected subjects (151). In the 
current work, after correcting for multiple hypotheses testing with the Benjamini-Hochberg 
procedure, no OTUs, gene families, or m/z features were significantly differentially abundant or 
expressed at a q-value threshold of 0.05. While this is, in part, due to the high number of OTUs, 
gene families, and m/z features, it may also be impacted by the health of our cohort. We defined 
COPD to include moderate lung function impairment, and significant differences have only been 
shown in severe COPD (3, 22, 31, 33, 34). The HIV infected patients in our cohort were well-
managed and all were on antiretrovirals at the time of sampling. Of the differences that we did 
see, the gene families are the most readily interpretable. In COPD, the top three under-expressed 
gene families were UPI0003497762: sodium:glutamate symporter (p = 3.9x10-5), 
UPI00037382D8: ABC transporter permease (p = 6.5x10-6), and UPI00047C6BBB: uracil 
transporter (p = 3.9x10-5), all of which had median RPK expression levels of 0. All of these gene 
families are involved in transporting nutrients into and within cells and the loss of their 
expression may indicate a shift in the nutrients available to the cell. 
By looking at pairs of datasets, we learned more about what each dataset can tell us than 
about the metabolism of the lung microbiome. The fact that we see negative correlations between 
pairs of datasets, even when they have been processed to provide the same information, indicated 
that the information from one dataset cannot make up for another. The negative correlations 
when comparing taxonomic assignments by 16S rRNA gene sequences and metatranscriptome 
sequences was not unexpected as the two approaches measure different things – presence of 
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DNA for the 16S rRNA gene sequences and expression of RNA for the metatranscriptome 
sequences. The negative correlations lend credence to the theory that genes and proteins that are 
important to the functioning of the ecosystem often originate in rare members of the community. 
This theory is also supported by the disagreement in direction of abundance or expression in 
nearly half of the KO terms (46% when comparing HIV infection and 49% when comparing 
COPD status).  
When the differential abundance or expression was significant, and the direction was the 
same in the predicted metagenome and the metatranscriptome, special attention was paid to these 
KO terms because they were so rare. Among these significantly different KO terms, we found 
terms known to be associated with the conditions in question. Pyruvate dehydrogenase, of which 
K00163 is a subcomponent (Table 4.2), has been shown to be over-expressed in HIV-1 infected 
cells in vitro (152). Similarly, glucokinase (K00845; Table 4.2) is required for HIV replication 
within cells (153). In contrast, we saw NADH dehydrogenase (ubiquinone) 1 alpha/beta 
subcomplex 1 (K03955; Table 4.3) under-abundant and under-expressed in COPD, but it has 
been shown to be over expressed in lung tumors from COPD patients compared to tumors from 
those with normal function (154). However, this study was examining human cells rather than 
the microbial community with which the cells are in contact.   
When we integrated all three datasets, we were able to gain new information about the 
metabolism of the lung microbiome. By integrating metabolomics with the 16S rRNA gene 
sequence-based OTUs and metatranscriptome sequence-based gene families, we were able to 
identify blocks that were enriched for metabolic functions. Among these functions was riboflavin 
metabolism, which was not identified as enriched in the lung microbial community by any of the 
datasets individually. While humans are capable of processing riboflavin, they are unable to 
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produce it. Through our block identification, we show the possibility that riboflavin is being 
produced locally in the lungs by the bacteria present. This has potential implications for lung 
injuries, as riboflavin administration has been shown in rats to protect against lung injury (155, 
156). COPD is the result of architectural damage to the lung (157) so expression of Riboflavin 
could potentially relieve the injury in this case too.  
While this is one of the first studies to integrate data from 16S rRNA gene sequences, 
metatranscriptomics, and metabolomics for the assessment of the lung microbiome, the current 
study suffers from a number of limitations. Due to uneven BAL fluid volumes and sequencing 
failures, our sample size was limited to 25. A larger sample size would lead to greater power to 
detect differences in COPD status and HIV infection. The mixture of HIV-infected and -
uninfected individuals and those with COPD and with normal lung function may also be seen as 
a limitation to our study. The heterogeneity of lung function and immune status may mask the 
metabolic functions of the community present in the healthy human lung. However, without this 
heterogeneity, we would not have been able to look for differentially abundant and expressed 
KO terms.  
The choices in reference databases place unmeasurable limitations on this and other -
omics studies. The limitations of reference databases are especially evident in our comparison of 
taxonomic assignments. For example, the genus Tropheryma is not in the GreenGenes database 
that is the default taxonomic reference for many analysis pipelines and was used for initial 16S 
rRNA gene sequence taxonomy assignments. This genus was seen in our metatranscriptome 
sequence taxonomy assignments and was confirmed as present in these samples with qPCR (data 
not shown). Tropheryma is highly relevant to the current study as it has been previously shown 
to be enriched in the lungs of HIV-infected patients (14). Another reference database limitation 
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is inherent in metabolomics studies. Only 1% of all possible m/z features can be mapped to 
metabolites in the current databases (158). This lack of identifiability is why we used 
mummichog to look at pathway enrichment among our blocks rather than metabolites. If the 
mapping of m/z features to metabolites were to improve, we could include metabolomics in more 
direct comparisons to the other -omics platforms.  
4.4 METHODS 
4.4.1 Patient Population 
To compare and integrate three -omics datasets, we identified a subset of samples for which we 
had 16S rRNA gene sequences, metatranscriptomic, and metabolomics data. The 25 samples 
used for this analysis originated from the Pittsburgh cohort of the Lung HIV Microbiome Project 
(LHMP). The larger cohort has been described in (4). Briefly, eligibility requirements included 
no use of antibiotics in the past three months and no evidence of acute respiratory disease for 
four weeks. The subset of 25 samples analyzed here originated from participants with the 
following characteristics: 19 HIV-infected and 6 HIV uninfected, 17 with COPD and 8 with 
normal lung function. Written informed consent was obtained from all participants after approval 
of human subjects’ protection protocols from review boards of the University of Pittsburgh, the 
University of California San Francisco, the University of California Los Angeles. 
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4.4.2 Sample and Sequence Processing 
The lung microbiome was sampled by bronchoalveolar lavage (BAL) following an oral wash and 
gargle with antiseptic mouthwash. BAL fluid was collected from patients and split into multiple 
aliquots that were stored at –80°C until further processing. One aliquot was used for 16S rRNA 
gene amplicon sequencing, one for metatranscriptome sequencing, and one for metabolomics 
profiling, as described below.  
For 16S rRNA gene amplicon sequencing, samples had DNA extracted using standard 
techniques with the PowerSoil® DNA Isolation Kit from MO BIO (Carlsbad, CA). The V4 
hypervariable region was amplified and sequenced on the Illumina MiSeq platform using the 
Caporaso protocol (159). The resulting 1.4 million high quality sequences were processed using 
QIIME version 1.9 (84). Sequences were clustered at 97% similarity using uclust (160) to form 
de novo operational taxonomic units (OTUs). The OTUs were assigned to taxonomies using the 
uclust method and the Greengenes database (62, 63). To predict the metagenomics potential of 
each sample based on the 16S rRNA sequences, we used QIIME to perform closed-reference 
OTU picking and the PICRUSt software (140) to assign KO term abundances (132, 133).   
For metatranscriptome sequencing, samples had RNA extracted using a modified version 
of Qiagen’s RNeasy Micro (Hilden, Germany) protocol. Each aliquot was centrifuged at 4500 x 
g for 5’ at 4°C. The supernatant was discarded and the cellular pellet was resuspended in 700L 
QIAzol (Qiagen) before transfer to 2mL MP Biomedicals’s Lysing Matrix B tubes (Santa Anna, 
California, USA). Samples were homogenized on a FastPrep-24 (MP Biomedicals) with two 
rounds at 6.0 m/s for 40s, then centrifuged at 10k x g for 2’ at 4°C. QIAzol reagent was added to 
the supernatant to bring the final volume back to 700L. For phase separation and cleanup, we 
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followed Qiagen’s protocol, including an on-column DNase I treatment. RNA was eluted in 30 
µl RNase-free water and checked for sample concentration and integrity before cDNA synthesis 
using the Nugen Ovation RNA-seq FFPE System (San Carlos, California, USA), according to 
the manufacturer’s protocol. Resulting cDNA samples were purified and size-adjusted using the 
Zymo Select-a-Size DNA Clean & Concentrator kit (Irvine, California, USA) to remove 
fragments below 200 base pairs. Sequencing libraries were prepared from 100ng of cDNA with 
New England Biolab’s NEBNext Ultra DNA Library Prep Kit for Illumina (Ipswitch, 
Massachusetts, USA). Individual libraries were prepared for multiplexing using the NEBNext 
Multiplex Oligos (Dual Index Primer Set 1, New England Biolabs) and were subjected to 8 
cycles of PCR amplification. Libraries were pooled in an equimolar ratio, diluted to 2nM, and 
5% PhiX was spiked-in to ensure sequence diversity. The library pool was split evenly across an 
Illumina HiSeq (San Diego, California, USA) flowcell using TruSeq SBS v3 chemistry for 
2x100bp read lengths and run on a HiSeq 2500 in high output mode. 
Prior to extracting RNA, we aliquoted 500µl of each sample for DNA metagenome 
sequencing and stored this at –80°C. DNA was extracted using the PowerSoil DNA Isolation Kit 
from MO BIO following the manufacturer’s protocol with the following exception: after the 
addition of Solution C1, each tube was incubated at 65°C for 10’ and run in a FastPrep-24 at 6.0 
m/s for 60s before continuing through the protocol. DNA was eluted in 60L 10mM Tris. 
Samples were diluted to 200 pg/L before library preparation with the Illumina Nextera XT 
DNA Library Preparation Kit according to the manufacturer’s protocol. Individual libraries were 
prepared for multiplexing using the Illumina Nextera XT index kit. Libraries were purified using 
0.5X volumes of Beckman Coulter Life Sciences AMPure XP beads (Indianapolis, Indiana, 
USA) before inspection and quantification. Libraries were combined in an equimolar ratio into 
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two pools to avoid barcode overlap, diluted to 4nM, and 5% PhiX was spiked-in to ensure 
sequence diversity. Each library pool was clustered per lane of an Illumina HiSeq flowcell using 
a HiSeq Rapid v2 SBS Kit for 2x250bp read lengths and run on a HiSeq 2500 in rapid run mode. 
The metatranscriptome and metagenome sequences were filtered to remove human and 
mitochondrial sequences using custom perl scripts available at https://github.com/ghedin-
lab/human-16s-phix-filter. The remaining 6.5 million metatranscriptome sequences total were 
processed using the HUMAnN2 pipeline (141), normalizing the RNA expression by the DNA 
abundance. UniRef50 transcript expression tables for each sample were joined and regrouped by 
KEGG terms. Taxonomic assignments were made using the Livermore Metagenomics Analysis 
Tool (LMAT), based on k-mers of size 30 (161). 
The metabolomics profiling of these samples was described in (151). Briefly, samples 
were analyzed by liquid chromatography-high-resolution mass spectrometry (LC-FTMS). Mass-
to-charge ratios (m/z features) were collected from m/z 85 to 1275 over 10 minutes. Adaptive 
processing software package (apLCMS) with xMSanalyzer was used for peak extraction, noise 
removal, and quantification of ion intensities (162). These data represent m/z features, not 
definitively identified metabolites. Using the mummichog (136) pipeline we assigned these m/z 
features to pathways using 100 permutations, including KEGG pathway terms. Where possible, 
we assigned these m/z features to metabolites using MetaboSearch (163), mapping to the 
Madison Metabolomics Consortium Database (MMCD) (164) and LipidMaps (165) databases 
with a match threshold of 1 ppm. The metabolite and KEGG identifications with the smallest 
mass difference were used.    
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4.4.3 Differential Abundance/Expression 
Differential abundance or expression was evaluated for both COPD and HIV in each dataset. For 
this comparison, COPD was defined as diffusing capacity of the lungs from carbon monoxide 
(DLCO) < 80% or forced expiratory volume in 1 second (FEV1) < 70% and compared to those 
with normal lung function. Similarly, individuals from which samples were obtained with HIV 
infections were compared to those who are HIV uninfected. All comparisons were made using 
Wilcoxon rank-sum test (166) and corrected for multiple hypotheses testing using the Benjamini-
Hochberg correction (94).  
We compared the differential abundance or expression of each KEGG term identified in 
each dataset. The KEGG terms from each dataset were normalized to the scale of 0 to 1. We then 
used a Wilcoxon rank-sum test to look for differential abundance and expression between HIV 
infected individuals and HIV uninfected individuals as well as between individuals with and 
without COPD. We then compared the list of KEGG terms identified as differentially abundant 
or expressed between datasets, as well as the direction (over abundant/expressed or under 
abundant/expressed) of all KEGG terms. 
4.4.4 Correlations 
We looked at Spearman correlations between pairs of datasets for associations between OTUs 
and gene families, between OTUs and m/z features, and between gene families and m/z features. 
Because OTUs were measured in relative abundances, correlations with this dataset were 
adjusted to partial correlations using the pcorr R package (167).    
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4.4.5 Block Identification 
In an attempt to determine associations across datasets, we ran a sparse multi-block partial least 
squares (sMBPLS) regression (134). This form of regression was developed to study gene 
regulation and expression based on multiple genomic datasets (including copy number variation, 
methylation, and microRNA expression levels). The sMBPLS regression method seeks to 
identify multi-dimensional blocks, blocks that include all types of datasets included in the 
regression, that are enriched for functional activity. The sMBPLS regression was performed 
using the R package msma (168). We used relative OTU abundance and relative gene family 
(UniRef50) expression as independent variables (X) to explain the m/z feature dependent 
variables (Y). The m/z features in resulting blocks were run through mummichog to identify 
functional pathway enrichment within each block (136). 
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5.0  CONCLUSIONS 
 
The work presented aimed to provide a quantitative assessment of the lung microbiome. Instead 
of listing the microbes detected within the lungs under different disease conditions, we ran 
sophisticated regression methods, inferred networks among the microbes, and characterized 
metabolic functions. The results enhance both our knowledge of the lung microbiome and the 
methodology available to analyze other host-associated microbiomes.  
First, we used a LassoGLMM to look for associations between microbes and continuous 
clinical variables. While we found no surprising associations between oral microbes and clinical 
blood measurements, nor between lung microbes and inflammation, we were able to demonstrate 
the effective and flexible capabilities of the LassoGLMM. This regression method can handle 
repeated measurements from the same individual, whether over a time course or multiple source 
locations, and the continuous nature of many clinical co-variables.  
Then, we looked at cross-domain interactions between bacteria and fungi found in the 
lungs and on the skin. By expanding the SPIEC-EASI method, we were able to do this in a 
statistically sound manner. We found that including cross-domain interactions creates more 
connected and robust networks than either the bacteria or fungal domains alone. The topography 
of these cross-domain networks can shed light on the community history and stability, including 
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robustness against perturbations such as antibiotics, that may not be apparent when examining a 
single domain of life. 
Finally, we examined the metabolism of the lung microbiome using three “-omics” 
technology datasets. We found that taxonomic assignments and predicted metabolic functions 
from 16S rRNA target gene sequencing are not in agreement with the taxonomic assignments 
and metabolic functions from metatranscriptome sequences. However, when we integrated these 
datasets with metabolomics, we were able to uncover enrichment for metabolic functions that 
would not have been discovered by any one platform alone. Thus, we provided a complete 
characterization of the metabolism of the lung bacterial microbiome.  
Future directions for each of these three sections include applying the methods to new 
microbiomes, testing hypotheses generated by the methods, and improving based on areas of 
active research. The LassoGLMM can be applied to new microbiome studies as longitudinal 
studies become more common and may be improved by incorporating more advanced penalty 
parameters and the option to include interactions between microbes. Any associations predicted 
between microbes and host characteristics are likely to be difficult to validate but bioreactors that 
imitate full ecosystems represent a possible testing environment. Cross-domain SPIEC-EASI 
networks can be built on any dataset that contains targeted amplicon sequencing of two or more 
domains, and, as we have shown, the predicted interactions can be validated by co-culturing 
experiments. Discussions are already underway to expand the SPIEC-EASI network framework 
to other -omics datasets such as metagenomics, which are cross-domain by nature. The 
description of the metabolism of the lung microbiome will continue to improve as the -omics 
technologies, as well as methods to analyze and integrate them, improve. Observations about the 
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lung microbiome metabolism that are generated by computational methods can then be tested in 
bioreactors and other laboratory set-ups that mimic the human lung environment. 
Overall, we were able to adapt and develop tools to examine host-associated 
microbiomes in quantitative and inferential ways. By applying these tools to the lung 
microbiome, we confirmed that the human lung contains an active microbial community, 
complete with interactions with its host and between its own members. The activity of this 
microbial community has the potential to impact the human immune system and respiratory 
health.  Additionally, the results in the preceding sections, and from other applications of the 
tools we adapted and developed, can be used to generate testable hypotheses about the impact of 
the microbiome on human health.  
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APPENDIX A 
LASSOGLMMFORMICROBIOMES.R 
### LassoGLMM for Microbiome Studies ### 
### Written by Laura Tipton          ### 
### Last edited: Jan 11, 2016        ### 
 
## Data should be in the following formats: 
# MBdat: 16S/ITS relative abundance data in 1 matrix, samples in rows and OTUs/species in columns with 
identifiable names 
# dat: continuous response varibles in 1 matrix, samples in rows and variables in columns with identifiable names 
# demos: categorical explanatory variables in 1 matrix, samples in rows and variables in columns with identifiable 
names 
# ids: identification random effect variables in 1 matrix, samples in rows and variables in columns with identifiable 
names 
# all rows in the above 4 matrices should be in the same order 
 
## Data cleanup, skip if data is already clean 
# relabun = function to calculate relative abundance, if not already in this format 
relabun <- function(x){ 
  sums <- apply(x, 1, sum, na.rm=TRUE) 
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  y <- x/sums 
  return(y) 
} 
 
# gt0 = function to count samples that contain OTUs  
gt0 <- function(vec){ 
  v <- as.numeric(vec) 
  s <- sum(v>0) 
  return(s) 
} 
 
# remove OTUs in less than 2 samples by applying gt0 function 
MBdat.gt0 <- as.matrix(apply(MBdat, 2, gt0)) 
MBdat2 <- MBdat[,-which(dat.gt0<2)] 
 
## Variable screening step based on Pearson Correlations 
# corrpairs = function to calculate Pearson correlations between all OTU-response variable pairs 
corrpairs <- function(ys, xs, fName="Correlations.csv", useQ=FALSE){ 
  sums <- apply(xs, 2, gt0) 
  res <- vector("list", length(ncol(ys))) 
  #names(res) <- colnames(ys) 
  for(i in 1:ncol(ys)){ 
    res[[i]] <- vector("list") 
    for(j in 1:ncol(xs)){ 
      c <- cor.test(ys[,i], xs[,j], na.rm=TRUE) 
      p <- c$p.value 
      q <- c$p.value*(ncol(ys)*ncol(xs)) 
      if (!is.na(p)){ 
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        c2 <- c(colnames(ys)[i], colnames(xs)[j], as.numeric(c$estimate), c$conf.in, p, q, sums[[j]]) 
        write(c2, file=fName, ncolumns=8, append=TRUE, sep=",")  
        if (useQ){ 
          if (q < 0.05){ 
            res[[i]] <- append(res[[i]], j) 
          } 
        } 
        else { 
          if (p < 0.05){ 
            res[[i]] <- append(res[[i]], j) 
          } 
        } 
      } 
    } 
    print(paste("Completed y variable ", i, ", ", colnames(ys)[i])) 
  } 
  return(res) 
} 
 
# calculate correlations, in order to move on, assign this to a variable (corrs) 
corr <- corrpairs(dat, MBdat2, fName="Correlations.csv") 
 
## Perform LassoGLMM 
# penGLMM = function to regress MBdat on dat accounting for demos and ids 
penGLMM <- function(ys, xs, corrs, randE, fName='Regression.txt', lam=seq(0,200,1), strat=NULL, 
rtrnmod=FALSE){ 
  require(glmmLasso) 
  for (i in 1:ncol(ys)){ 
 140 
    vars <- unlist(corrs[[i]]) 
    vars2 <- colnames(xs)[vars] 
    vars3 <- '' 
    for (j in 1:length(vars2)){ 
      vars3 <- paste(vars3, vars2[j], sep="+") 
    } 
    tmp <- data.frame(na.omit(cbind(ys[,i], xs, randE))) 
    colnames(tmp) <- c(colnames(ys)[i], colnames(xs), colnames(randE)) 
    ranEf <- list() 
    for(k in 1:ncol(randE)){ ranEf <- append(ranEf, as.formula(paste(colnames(randE)[k], "=~1"))); 
names(ranEf)[[k]] <- colnames(randE)[k]} 
    if (!is.null(strat)){ 
      tmp <- data.frame(na.omit(cbind(ys[,i], xs, randE, strat))) 
      colnames(tmp) <- c(colnames(ys)[i], colnames(xs), colnames(randE), colnames(strat)) 
      for (k in 1:ncol(strat)){ 
        vars3 <- paste(vars3, paste0("as.factor(",colnames(strat)[k],")"), sep="+") 
      } 
    } 
    tmp[,c(1:ncol(xs)+1)] <- apply(tmp[,c(1:ncol(xs)+1)],2, as.numeric) 
    tmp[,c((ncol(xs)+2):(ncol(xs)+ncol(randE)+1))] <- apply(tmp[,c((ncol(xs)+2):(ncol(xs)+ncol(randE)+1))], 2, 
as.factor) 
    min <- Inf 
    lamb <- 0 
    minmod <- list() 
    minmod$coefficients <- 0 
    minmod$ranef <- 0 
    for (l in lam){ 
      try({ 
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        mod <- glmmLasso(fix=as.formula(paste("tmp[,1]~", substr(vars3,2,nchar(vars3)))), rnd=ranEf, 
data=data.frame(tmp), lambda=l, control=list(q_start=diag(0.1, ncol(randE)))) 
        if (mod$bic < min){ 
          minmod <- mod 
          min <- mod$bic 
          lamb <- l 
        } 
      }, silent=T) 
    } 
    write(paste("Y =", colnames(ys)[i]), file=fName, append=T) 
    write("Fixed Effects:", file=fName, append=T) 
    write.table(as.matrix(minmod$coefficients[abs(minmod$coefficients)>0]), file=fName, append=T) 
    write("Random Effects:", file=fName, append=T) 
    write.table(as.matrix(minmod$ranef), file=fName, append=T) 
    write(paste("Optimal Lamba: ", lamb), file=fName, append=T) 
    write(paste("Minimum BIC: ", min), file=fName, append=T) 
    write(paste(""), file=fName, append=T) 
    print(paste("Completed y variable ", i, ", ", colnames(ys)[i])) 
    if (rtrnmod){ return(minmod) } 
  } 
} 
 
# apply LassoGLMM, this does not need to be assigned to a variable 
penGLMM(dat, MBdat2, corr, ids, strat=demos) 
 
## Plotting example 
require(car) 
par(family="sans") 
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# create a temporary dataset sorted by response variable of interest (using 1 in this example and assuming OTU-1 is 
strongly associated) 
tmpplot <- cbind(MBdat2[order(dat[,1]),], dat[order(dat[,1]),1]) 
 
# plot a "none" plot to set axes and labels 
matplot(log(tmpplot[-which(tmpplot[,1]==0),1]), tmpplot[-which(tmpplot[,1]==0),ncol(tmpplot)], pch=19, 
type="n", ylab="Response Variable", xlab="log relative abundance", main="OTU-1") 
 
# plot grey dashed lines for all responses 
for(i in 1:nrow(tmpplot)){ lines(c(-20,20), c(tmpplot[i,ncol(tmpplot)], tmpplot[i,ncol(tmpplot)]), lty=2, col="grey")} 
 
# finally plot abundances in red 
matplot(log(tmpplot[-which(tmpplot[,1]==0),1]), tmpplot[-which(tmpplot[,1]==0),ncol(tmpplot)], pch=19, 
type="o", add=TRUE, col="red") 
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APPENDIX B 
SOP FOR CO-CULTURING MICROBES 
1. PURPOSE 
 
1.1. To examine how microbes (both bacteria and fungi) grow together compared to 
separately. 
1.2. To validate the following interactions predicted using the SPIEC-EASI software: 
1.2.1. Emericella nidulans and Propionibacterium acnes (positive) 
1.2.2. Emericella nidulans and Rothia dentocariosa (negative) 
1.2.3. Propionibacterium acnes and Rothia dentocariosa (negative) 
1.2.4. Emericella nidulans, Propionibacterium acnes, and Rothia dentocariosa 
(negative) 
 
 
2.  REQUIREMENTS 
Microbes     Ethanol and bleach spray bottles 
2 mL serological pipette tips and aid 
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Bunsen burner, striker, and gas line  Malt extract agar 
Sterile water     Untreated culture plates 
10 mL Falcon/culture tubes   Hot plate with stir bar 
Tweezers     Disposable inoculum loops 
Camera     Hemocytometer and cover slips 
Microscope     P100 pipetteman and tips 
Brain-Heart Infusion (BHI) media mix LB media mix 
Cryotubes     Parafilm 
Trypticase soy agar pre-poured plates with 5% defibrinated sheep’s blood (TSA) 
74 mm2 untreated Nest culture flasks  Dry ice 
Black light lamp    Agar 
  
 
3. NOTES 
 
 3.1. Protocol v1.01 is written for those microbes under investigation in April 2016 and 
will need to be modified for any future test of predicted interactions.  
 
 3.2. Microbes under investigation in April 2016 are: 
  3.2.1  Emericella nidulans (aka Aspergillus nidulans) 
  3.2.2  Propionibacterium acnes 
  3.2.3 Rothia dentocariosa 
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4.  Rehydrate and Grow Stock – E nidulans 
When opening the vial, wear goggles and work above a tray to catch glass fragments. 
4.0  Clean and disinfect biosafety cabinet (BSC). Flame sterilize and fill 10 mL Falcon 
tube with 6 mL of sterile water. Set up and light Bunsen burner. 
4.1 Heat tip of E nidulans vial in Bunsen burner flame. Turn off Bunsen burner! 
4.2 Squirt a few drops of water on the hot tip to crack glass. 
4.3 Strike hot tip with file or pen to remove tip – make sure fragments go in tray! 
4.4 Remove insulation and inner vial with tweezers. Gently raise cotton plug with 
flame sterilized and cooled tweezers. 
4.5 Add .75 mL sterile water (from MilliQ spout) to inner vial, stir to form a 
suspension. 
4.6 Draw up entire contents into pipette and transfer to 10 mL Falcon tube of sterile 
water. 
4.7 Sterilize empty vials and fragments with ethanol prior to disposal in sharps bin. 
4.8 Rehydrate at room temperature overnight. 
4.9  (Next day, can be performed on the “bacteria” bench) Mix 12.5 g malt extract 
agar, 7 g glucose, and 250 mL distilled water. Bring to a boil on a hot plate, using 
a stir bar. 
4.10 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
4.11 Pour media into 3-4 culture plates. Wait for plates to solidify. 
4.12 Mix rehydrated fungus well with pipette. 
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4.13 Drop “several” drops totaling about 1 mL of rehydrated fungus onto each of 3 
malt extract agar plates. 
4.14 Smear drops over plate using fresh, sterile inoculum loop. 
4.15 Incubate at 24°C for 72 hours, periodically check for growth by visual inspection. 
Store remaining rehydrated fungus at 4°C until growth is confirmed. 
4.16 After 72 hours of incubation, assuming good growth, photograph plates, inspect 
cells under microscope.  
4.17 Count cells on hemocytometer to determine concentration and practice 
hemocytometer technique: 
4.17.1  Clean hemocytometer and cover slip with ethanol, moisten coverslip with 
water and affix to hemocytometer. 
4.17.2 From 1 plate scrape 1 “colony” with inoculum loop into sterile water, mix 
well. 
 4.17.3 Pipette 100 uL of water and cell mixture into loading port on  
hemocytometer. 
4.17.4 Place hemocytometer under microscope, count cells in appropriate 
squares, photograph each square, and multiply the average cell count by 
104 to determine cells/mL. 
 
5.  Freezing and Storing – E nidulans 
 
5.1 Seal 1 plate with parafilm and store upside down in 4°C.  
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5.2 Mix 5 g LB mix in 250 mL sterile water, autoclave for 15 minutes at 121°C, let 
cool. 
5.3 Mix 9.25 g Brain-Heart Infusion mix in 250 mL sterile water, heat to boil with a 
stir bar, and autoclave for 15 minutes at 121°C, let cool. 
5.4 From 1 plate, scrape each colony (being sure to get the edge of the colony where 
new growth is happening) into labeled cryotubes containing .5 mL LB and pipette 
up and down to resuspend. 
5.6 From the last plate, scrape each colony (being sure to get the edge of the colony 
where new growth is happening) into labeled cryotubes containing .5 mL BHI and 
pipette up and down to resuspend. 
5.7 Add .5 mL 15% glycerol to each cyrotube and shake to mix. Freeze at -80°C.    
   
 
6.  Rehydrate and Create Stocks – P. acnes 
Note that P acnes is an aerotolerant bacteria and all efforts should be made to reduce the 
oxygen exposure. This means that work should be done near a flame and, if possible, an 
anaerobic gas mixture or carbon dioxide gas should be blown over the tubes and plates to 
reduce the oxygen content in the headspaces. 
6.0 Clean and disinfect bacterial bench. Set up and light Bunsen burner. Flame 
sterilize and fill 10 mL Falcon tube with 6 mL of BHI media.  
6.1 Set 3 TSA plates around Bunsen burner. 
6.2 Flame sterilize and cool tweezers and the top of the vial containing P acnes. 
6.3 Carefully open vial and remove rubber stopper with tweezers. 
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6.4 Add .75 mL BHI to vial, stir, without creating air bubbles, to form a suspension. 
6.5 Draw up entire contents into pipette and transfer to 10 mL Falcon tube of BHI. 
6.6 Drop several drops totaling about 1 mL of rehydrated bacteria onto each of the 3 
TSA plates. 
6.7 Smear drops over plate using fresh, sterile inoculum loop. Immediately close 
plate.  
6.8 Shut off Bunsen burner. Seal remaining rehydrated bacteria in Falcon tube with 
parafilm and store at 4°C until growth is confirmed. 
6.9 After sufficient drying time, seal plates with parafilm. 
6.10 Incubate at 37°C for 48-72 hours, periodically check for growth and 
contamination by visual inspection. 
6.11 After 72 hours of incubation, assuming good growth, photograph plates, inspect 
cells under microscope. Check for orange glow under black light.  
6.12 Count cells on hemocytometer to determine concentration and practice 
hemocytometer technique (see step 4.17). 
 
7.  Freezing and Storing – P acnes 
  
 7.1 Seal 1 plate with parafilm and store upside down in 4°C. 
 7.2 Make more LB and/or BHI broth if needed (see sections 5.2 and 5.3). 
 7.3 From 1 plate, scrape each colony (being sure to get the edge of the colony  
where new growth is happening) into labeled cryotubes containing .5 mL LB and 
pipette up and down to resuspend. 
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 7.4 From the last plate, scrape each colony (being sure to get the edge of the  
colony where new growth is happening) into labeled cryotubes containing  
.5 mL BHI and pipette up and down to resuspend. 
 7.5 Add .5 mL 50% glycerol to each cyrotube and shake to mix. Freeze at 
 -80°C. 
 
8. Rehydrate and Create Stocks – R. dentocariosa 
 
8.0 Clean and disinfect bacteria bench. Flame sterilize and fill 10 mL Falcon tube of 
BHI broth (make more if necessary).  
8.1 Mix 9.25 g BHI media, 3.75 g agar, and 250 mL distilled water. Bring to a boil on 
a hot plate using a stir bar. 
8.2 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
8.3 Pour media into 3-4 culture plates. Wait for plates to solidify. 
8.4 Open R dentocariosa vial according to ATCC instructions (see sections 4.1-4 or 
6.3).  
8.5 Add .75 mL BHI to vial, stir to form a suspension. 
8.6 Draw up entire contents into pipette and transfer to 10 mL Falcon tube of  
BHI. 
8.7 Drop “several” drops totaling about 1 mL of rehydrated bacteria onto each of 3 
BHI plates. 
8.8 Smear drops over plate using fresh, sterile inoculum loop. 
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8.9 Incubate at 37°C for 24-48 hours, periodically check for growth by visual 
inspection. Store remaining rehydrated bacteria at 4°C until growth is confirmed. 
8.10 After 48 hours of incubation, assuming good growth, photograph plates, inspect 
cells under microscope. Check for coral glow under black light. 
8.11 Count cells on hemocytometer to determine concentration and practice 
hemocytometer technique (see section 4.17) 
  
9. Freezing and Storing – R dentocariosa 
 
 9.1 Seal 1 plate with parafilm and store in 4°C. 
9.2 Make more BHI broth if needed (see section 5.3). 
 9.3 From remaining plates, scrape each colony (being sure to get the edge of  
the colony where new growth is happening) into labeled cryotubes containing .5 
mL BHI and pipette up and down to resuspend. 
 9.4 Add .5 mL 50% glycerol to each cyrotube and shake to mix. Freeze at  
-80°C. 
 
10. Grow Microbes Under Uniform Conditions 
This section is written to be done at 1 time for all 3 microbes, but can be broken down into 2-3 
groups, depending on confidence and ability of experimenter(s). 
10.1 Mix 55.5 g BHI media, and 1.5 L distilled water. Bring to a boil on a hot plate 
using a stir bar. 
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10.2 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
10.3 Clean and disinfect BSC.  
10.4 Pipette 10 mL BHI media into each of 12 Nest culture flasks. 
10.5 Remove a cryotube of each microbe stored in BHI from the -80 freezer, store on 
dry ice. 
10.6 Using a fresh, sterile inoculum loop for each microbe, scrape the top of the  
frozen media and place in labeled culture flask, stirring to mix. 
10.7 Repeat 12.6 twice for each microbe, resulting in 3 flasks of each microbe. 
10.8 For E nidulans: using a fresh, sterile inoculum loop, scrape the top of the frozen 
media and streak fungus onto a malt extract agar plate created in 4.11. This will 
serve as control that the frozen stock survived and that the fungus can grow at the 
higher temperature. 
10.9 For P acnes: using a fresh, sterile inoculum loop, scrape the top of the frozen 
media and streak onto a TSA plate. This will serve as a control that the frozen 
stock survived. 
10.10 Incubate at 37°C with mild shaking overnight to 24 hours. 
10.11 Mix 37 g BHI media, 15 g agar, and 1 L distilled water. Bring to a boil on a hot 
plate using a stir bar. 
10.12 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
10.13 Pour media into 16-20 culture plates. Wait for plates to solidify. 
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10.14 After incubation, check growth every 3-6 hours (subject to sufficient change in 
growth in that time). To check growth: 
 10.14.1 Photograph the flasks.  
 10.14.2 Pipette up and down several times to ensure a representative  
sample. Remove 150-200 uL from the flask to an Eppendorf tube. 
 10.14.3 Take 100 uL from the Eppendorf tube to count on a  
hemocytometer following step 4.17. 
10.14.4 At every other time point (every 6-12 hours), drop remaining ~100 
uL onto a BHI plate, and smear using a fresh, sterile inoculum 
loop. Make sure this plate is labeled with the time. 
10.14.5 Return flasks and new plate(s) to incubator. 
10.15  After incubation and through the end of all experiments, maintain a serial culture 
for each microbe using serial splitting just prior to log phase growth (presumably 
splitting every ~24 hours). To do this, take 1 mL of the current serial culture and 
add to a flask containing 9 mL new BHI media. Periodically store a serial split at 
4°C after the 1 mL has been removed and/or create a frozen stock by mixing .5 
mL of culture with .5 mL of 50% glycerol and store at -80°C.  
10.16 Check timed plates (created in 12.14.4) after 24 hours (subject to sufficient 
growth), count colonies as colony forming units.  
10.17 Stop taking measurements when no change or negative growth has been observed 
for 3 consecutive time points. 
 
11. Dual Cultures 
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This section is written to be done at 1 time for all 3 pairs of microbes but can be broken down 
into 2-3 groups, depending on the confidence and ability of the experimenter(s).  
11.1 Mix 74 g BHI media and 2 L distilled water. Bring to a boil on a hot plate using a 
stir bar. 
11.2 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
11.3 Pipette 10 mL BHI media into each of 18 Nest culture flasks. 
11.4 Based on concentration, pipette XXX cells from latest serial culture (see step 
12.15) of microbe A into newly labeled flask. 
11.5 Based on concentration, pipette XXX cells from latest serial culture of microbe B 
into same labeled flask. 
11.6 Repeat steps 13.5 and 13.6 twice more resulting in 3 flasks for the pair microbe A 
and microbe B.  
11.7  Repeat steps 13.5-7 for every pair of microbes (see sections 1.5.1-6) which should 
result in 18 flasks. 
11.8 Incubate at 37°C with mild shaking overnight to 24 hours. 
11.9 Mix 37 g BHI media, 15 g agar, and 1 L distilled water. Bring to boil on a hot 
plate using a stir bar. 
11.10 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
11.11 Pour media into 16-20 culture plates. Wait for plates to solidify. 
11.12 After incubation, check growth every 3-6 hours (subject to sufficient change in 
growth in that time in monocultures). Check growth following steps 12.14.1-5. 
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Additionally, photograph and count the cells under the black light for dual 
cultures containing C minutissium and P acnes. 
11.13 Check timed plates after 24 hours (subject to sufficient growth), count colonies as 
colony forming units. 
11.14 Stop taking measurements when no change or negative growth has been observed 
for 3 consecutive time points. 
 
12. Tri-cultures  
12.1 Mix 37 g BHI media and 1 L distilled water. Bring to a boil on a hot plate using a 
stir bar. 
12.2 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
12.3 Clean and disinfect BSC.  
12.4 Pipette 10 mL BHI media into each of 18 Nest culture flasks. 
12.5 Based on concentration, pipette XXX cells from latest serial culture (see step 
10.15) of microbe A into newly labeled flask. 
12.6 Based on concentration, pipette XXX cells from latest serial culture of microbe B 
into same labeled flask. 
12.7 Based on concentration, pipette XXX cells from latest serial culture of microbe C 
into same labeled flask. 
12.8 Repeat steps 12.5 and 12.6 twice more resulting in 3 flasks for the triad microbes 
A, B, and C. 
12.9 Incubate at 37°C with milk shaking overnight to 24 hours. 
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12.10 Mix 37 g BHI media, 15 g agar, and 1 L distilled water. Bring to boil on a hot 
plate using a stir bar. 
12.11 Autoclave media at 115°C for 10 minutes, let cool until it can be handled without 
burning hands. 
12.12 Pour media into 16-20 culture plates. Wait for plates to solidify. 
12.13 After incubation, check growth ever 3-6 hours (subject to sufficient change in 
growth in that time in monocultures). Check growth following steps 10.14.1-5. 
Additionally, photograph and count the cells under the black light for tri-cultures 
containing C minutissium and P acnes. 
12.14 Check timed plates after 24 hours (subject to sufficient growth), count colonies as 
colony forming units. 
12.15 Stop taking measurements when no change or negative growth has been observed 
for 3 consecutive time points. 
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